glucose, (beta-d)-isomer has been researched along with thiophenes in 314 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (0.64) | 18.7374 |
| 1990's | 2 (0.64) | 18.2507 |
| 2000's | 3 (0.96) | 29.6817 |
| 2010's | 271 (86.31) | 24.3611 |
| 2020's | 36 (11.46) | 2.80 |
| Authors | Studies |
|---|---|
| Aker, DO; Conroy, MC; Devall, LJ; Thueson, DO; Wright, CD | 1 |
| Cohn, M; Eldor, A; Matzner, Y | 1 |
| Alberto, P; Giger, K; Nagel, G; Senn, HJ; Sonntag, RW | 1 |
| Arányi, P; Erdö, F; Németh, K; Székely, JI; Török, K | 1 |
| Bradley, H; Duane, RM; Murphy, PV; O'Boyle, KM; O'Brien, A; Pitt, N; Wilson, SJ | 1 |
| Golab, M; Skwarlo-Sonta, K | 1 |
| Arnold, B; Kolaczkowska, E; Opdenakker, G; Piccard, H; Plytycz, B | 1 |
| Hongu, M; Kawanishi, E; Kimata, H; Koga, Y; Nakayama, K; Nomura, S; Sakamaki, S; Sakamoto, T; Tsuda-Tsukimoto, M; Ueta, K; Yamamoto, Y | 1 |
| Chien, S; Demarest, K; Devineni, D; Ghosh, A; Polidori, D; Rothenberg, P; Sha, S; Shalayda, K; Wexler, D | 1 |
| Cassader, M; Gambino, R; Musso, G; Pagano, G | 1 |
| Heger, M | 1 |
| Basile, J | 1 |
| Dai, Y; Wang, L; Wang, WJ; Wang, Y; Yang, TT; Ye, WC; Zhang, LH; Zhang, QW; Zhang, XQ | 1 |
| Akinlade, B; Klasen, S; Kowalski, D; Schwartz, SL; Wilpshaar, W; Zhang, W | 1 |
| Kadokura, T; Krauwinkel, WJ; Smulders, RA; Veltkamp, SA | 1 |
| Cho, SH; Kang, M; Kim, J; Kim, JY; Lee, J; Lee, JS; Lee, SH; Park, HJ; Song, KS | 1 |
| Hayashizaki, Y; Imamura, M; Kihara, R; Kobayashi, Y; Kurosaki, E; Noda, A; Qun, L; Sasamata, M; Shibasaki, M; Tahara, A; Takasu, T; Tomiyama, H; Yamajuku, D; Yokono, M | 2 |
| Devineni, D; Hompesch, M; Morrow, L; Murphy, J; Schwartz, S; Skee, D; Vandebosch, A; Ways, K | 1 |
| Arakawa, K; Conway, B; Conway, J; Demarest, K; Du, F; Kuriyama, C; Liang, Y; Liu, Y; Martin, T; Matsushita, Y; Polidori, D; Ueta, K; Ways, K; Xu, J | 1 |
| Aggarwal, N; Arbit, D; Canovatchel, W; Capuano, G; Polidori, D; Rosenstock, J; Usiskin, K; Zhao, Y | 1 |
| Ikegai, K; Imamura, M; Kobayashi, Y; Koide, T; Kosakai, K; Kurosaki, E; Murakami, T; Nakanishi, K; Noda, A; Ogiyama, T; Ohkura, Y; Ohta, M; Shiraki, R; Suzuki, T; Takeuchi, M; Tomiyama, H; Yokota, M | 1 |
| Simonyi, G | 1 |
| Capuano, G; Nicolle, LE; Usiskin, K; Ways, K | 1 |
| Kadokura, T; Keirns, J; Krauwinkel, WJ; Smulders, RA; van Dijk, J; Veltkamp, SA; Zhang, W | 1 |
| Nyirjesy, P; Usiskin, K; Ways, K; Zhao, Y | 1 |
| Collins, C; Kadokura, T; Smulders, RA; van Bruijnsvoort, M; van Dijk, J; Veltkamp, SA | 1 |
| Komala, MG; Mather, A; Panchapakesan, U; Pollock, C | 1 |
| Dawid, C; Hofmann, T | 1 |
| Dhanjal, P; Ferrannini, E; Fonseca, VA; Houzer, A; Wilding, JP; Wilpshaar, W | 1 |
| Alba, M; Canovatchel, W; Cefalu, WT; Kim, KA; Meininger, G; Stenlöf, K; Tong, C; Usiskin, K | 1 |
| Forst, T; Rosak, C | 1 |
| Chen, LH; Leung, PS | 1 |
| Ferrannini, E; Kadokura, T; Smulders, RA; Veltkamp, SA | 1 |
| Kolanczyk, DM; Nisly, SA; Walton, AM | 1 |
| Ciaraldi, TP; Farrell, K; Ghosh, A; Henry, RR; Mudaliar, S; Polidori, D; Rothenberg, P; Sha, S; Vaccaro, N | 1 |
| Bakris, G; Cariou, B; David-Neto, E; Figueroa, K; Meininger, G; Usiskin, K; Wajs, E; Xi, L; Yale, JF; Yue, D | 1 |
| Kurosaki, E; Ogasawara, H | 1 |
| Canovatchel, W; Fu, M; Gross, JL; Guarisco, M; Kawaguchi, M; Meininger, G; Rosenstock, J; Schernthaner, G; Yee, J | 1 |
| Ghosh, A; Heise, T; Plum-Mörschel, L; Polidori, D; Rothenberg, P; Sha, S | 1 |
| Davis, SN; Lamos, EM; Younk, LM | 1 |
| Traynor, K | 1 |
| Curtin, CR; Devineni, D; Gutierrez, MJ; Murphy, J; Polidori, D; Rothenberg, PL; Rusch, S | 1 |
| Bode, B; Fung, A; Stenlöf, K; Sullivan, D; Usiskin, K | 1 |
| Hayashizaki, Y; Imamura, M; Kihara, R; Kobayashi, Y; Kurosaki, E; Li, Q; Noda, A; Sasamata, M; Shibasaki, M; Tahara, A; Takasu, T; Tomiyama, H; Yamajuku, D; Yokono, M | 2 |
| Bloomgarden, Z | 1 |
| Elkinson, S; Scott, LJ | 1 |
| Kadokura, T; Keirns, J; Krauwinkel, WJ; Lasseter, KC; Plumb, L; Smulders, R; Townsend, RW; Ushigome, F; Zhang, W | 1 |
| Lange-Chenier, H | 1 |
| Harris, KB; Riser Taylor, S | 1 |
| Freeman, JS | 1 |
| Johnson, MS | 1 |
| Inagaki, N; Kondo, K; Kuki, H; Maruyama, N; Susuta, Y; Yoshinari, T | 1 |
| Gebel, E | 1 |
| Babu, A | 1 |
| Hongu, M; Kawanishi, E; Kimata, H; Koga, Y; Kuriyama, C; Matsushita, Y; Nakayama, K; Nomura, S; Sakamaki, S; Sakamoto, T; Tsuda-Tsukimoto, M; Ueta, K; Yamamoto, Y | 1 |
| Arias, P; Balis, DA; Canovatchel, W; Cefalu, WT; Leiter, LA; Meininger, G; Niskanen, L; Xie, J; Yoon, KH | 1 |
| Diamant, M; Morsink, LM | 1 |
| de Zeeuw, D; Desai, M; Fulcher, G; Jiang, J; Mahaffey, KW; Matthews, D; Meininger, G; Neal, B; Perkovic, V; Shaw, W; Stein, P; Vercruysse, F | 1 |
| Abeyratne, A; Dietz, A; Kadokura, T; Keirns, J; Krauwinkel, W; Smulders, R; Zhang, W | 1 |
| Jungemann, S; Van Gilder, D | 1 |
| Andrianesis, V; Doupis, J | 1 |
| Hernandez, GT; Said, S | 1 |
| Canovatchel, W; Davidson, J; Januszewicz, A; Lavalle-González, FJ; Meininger, G; Qiu, R; Tong, C | 1 |
| Bagga, P; Biswas, D; Kamal, MA; Rizvi, SM; Shaikh, S; Shakil, S | 1 |
| Alba, M; Canovatchel, W; Cefalu, WT; Edwards, R; Jodar, E; Kim, KA; Meininger, G; Stenlöf, K; Tong, C | 1 |
| He, T; Lan, MC; Li, M; Wen, LR | 1 |
| Kawanishi, E; Koga, Y; Kuriyama, C; Matsushita, Y; Nomura, S; Sakamaki, S; Ueta, K; Yamamoto, Y | 1 |
| Black, S; Canovatchel, W; Charpentier, G; González-Gálvez, G; Hollander, P; Law, G; Mathieu, C; Meininger, G; Usiskin, K; Vercruysse, F; Wilding, JP | 1 |
| Akhtar, N | 1 |
| Vouyiouklis, M | 2 |
| Bays, HE; Canovatchel, W; Law, G; Weinstein, R | 1 |
| Gilbert, RE | 3 |
| Baker, WL; Nigro, SC; Pheng, M; Riche, DM | 1 |
| Dietrich, E; Powell, J; Taylor, JR | 1 |
| Davis, SN | 1 |
| Balis, DA; Meininger, G; Tong, C | 1 |
| Grassos, CE; Kallikazaros, IE; Katsi, VK; Lekakis, JP; Makris, TK; Michalakeas, CA; Stefanadis, CI; Tousoulis, D; Vamvakou, GD | 1 |
| Doggrell, SA; McIntyre, K | 1 |
| Scheen, AJ | 4 |
| Capuano, G; Fung, A; Nicolle, LE; Usiskin, K | 1 |
| Fukazawa, M; Hiramatsu, M; Honda, K; Kawabe, Y; Matsumoto, M; Suzuki, M; Suzuki, Y | 1 |
| García, SD | 1 |
| Mauricio, D | 1 |
| Mikhail, N | 2 |
| Seufert, J | 2 |
| Matthaei, S | 1 |
| Schnell, O | 1 |
| Hayashizaki, Y; Kihara, R; Kurosaki, E; Li, Q; Mitsuoka, K; Miyoshi, S; Muramatsu, Y; Sasamata, M; Shibasaki, M; Tahara, A; Takasu, T; Tomiyama, H; Uchiyama, Y; Yokono, M | 1 |
| Gonzalez-Saldivar, G; Rodríguez-Gutiérrez, R | 1 |
| Keller, DL | 1 |
| Bailey, RA; Blonde, L; Damaraju, CV; Martin, SC; Meininger, GE; Rupnow, MF | 1 |
| Capuano, G; Fung, A; Mayer, C; Nyirjesy, P; Sobel, JD; Usiskin, K; Ways, K | 1 |
| Forst, T; Goldenberg, R; Guthrie, R; Meininger, G; Stein, P; Vijapurkar, U; Yee, J | 1 |
| Chen, J; Cuyckens, F; Devineni, D; Evans, DC; Johnson, MD; Kalamaridis, D; Kelley, MF; Lim, HK; Lin, R; Mamidi, RN; Scheers, E; Sha, S; Silva, J | 1 |
| Ferrannini, E; Mari, A; Polidori, D | 1 |
| Bakris, GL; Oliva, RV | 1 |
| Kumar, M; Kumar, R; Mahapatra, MK; Malla, P | 1 |
| Dungo, RT; Poole, RM | 1 |
| Condren, AB; Donahue, EP; Farmer, TD; Healey, EC; Kim, K; McCoy, GA; O'Brien, TP; Printz, RL; Shiota, M; Ueta, K | 1 |
| Devineni, D; Polidori, D; Rusch, S; Vaccaro, N; Wajs, E | 1 |
| Bode, B; Desai, M; Fung, A; Harris, S; Mayer, C; Meininger, G; Shaw, W; Sinclair, A; Usiskin, K; Vijapurkar, U | 1 |
| Edwards, R; Kline, I; Usiskin, K; Weir, MR; Xie, J | 1 |
| Musetti, C; Quaglia, M; Stratta, P | 2 |
| Plosker, GL | 1 |
| Baggett, S; Elmore, LK; Kyle, JA; Skelley, JW | 1 |
| Guthrie, R; Slee, A; Traina, S | 1 |
| Fung, A; Kline, I; Mayer, C; Meininger, G; Usiskin, K | 1 |
| Goto, K; Kashiwagi, A; Kazuta, K; Ueyama, E; Utsuno, A; Yoshida, S | 1 |
| Farrell, K; Heise, T; Natarajan, J; Plum-Mörschel, L; Polidori, D; Rothenberg, P; Sha, S; Sica, D; Wang, SS | 1 |
| Chung, SH; Kim, GW | 1 |
| Bakris, G; Cariou, B; David-Neto, E; Figueroa, K; Jiang, J; Law, G; Meininger, G; Nieto, J; Usiskin, K; Wajs, E; Yale, JF; Yue, D | 1 |
| Inagaki, N; Kondo, K; Kuki, H; Susuta, Y; Takahashi, N; Yoshinari, T | 1 |
| Dou, J; Lu, J; Zhang, Q | 1 |
| Bakris, G; Davies, M; de Zeeuw, D; Kline, I; Mayer, C; Meininger, G; Perkovic, V; Usiskin, K; Vijapurkar, U; Woo, V; Yamout, H | 1 |
| Artis, E; Berg, JK; Devineni, D; Morrow, L; Polidori, D; Rusch, S; Stein, P; Vaccaro, N | 1 |
| Huang, YL; Lai, D; Shen, HP; Yang, XP; Zhong, XY | 1 |
| Bryant, S; De Jonghe, S; Feyen, B; Johnson, MD; Kelley, MF; Lammens, G; Louden, C; Ma, JY; Mamidi, RN; Moesen, E; Proctor, J; Snook, S; Vinken, P; Ways, K | 1 |
| Akiyama, N; Kadokura, T; Kageyama, S; Kashiwagi, A; Kazuta, K; Nagase, I; Smulders, R; Utsuno, A; Yoshida, S | 1 |
| Arnolds, S; Demarest, K; Devineni, D; Ghosh, A; Hompesch, M; Morrow, L; Polidori, D; Rothenberg, P; Sha, S; Spitzer, H | 1 |
| Dieu Van, NK; Han, P; Ji, L; Liu, Y; Meininger, G; Qiu, R; Vijapurkar, U; Yang, G | 1 |
| Furihata, K; Inagaki, N; Ishii, M; Kondo, K; Kuki, H; Sakai, M; Yoshinari, T | 1 |
| Arias, P; Balis, DA; Canovatchel, W; Langslet, G; Leiter, LA; Meininger, G; Millington, D; Vercruysse, F; Xie, J; Yoon, KH | 1 |
| Arakawa, K; Hikida, K; Kakimoto, T; Kimata, H; Kuriyama, C; Lee, SP; Matsushita, Y; Nakayama, K; Qi, J; Saito, A; Shiotani, M; Taniuchi, N; Ueta, K; Watanabe, Y; Xu, JZ | 1 |
| Christensen, M; Gluud, LL; Knop, FK; Storgaard, H; Vilsbøll, T | 1 |
| Nauck, MA | 1 |
| Brunton, S; Reid, TS | 1 |
| Altomare, CD; Belviso, BD; Caliandro, R; Colucci, M; de Candia, M; Incampo, F; Lopopolo, G; Zaetta, G | 1 |
| De Jonghe, S; Feyen, B; Geys, H; Johnson, MD; Mamidi, RN; Marien, D; Proctor, J; Vinken, P; Wynant, I | 1 |
| Hayashizaki, Y; Kurosaki, E; Tahara, A; Takakura, S; Takasu, T | 1 |
| Kadokura, T; Keirns, J; Krauwinkel, W; Leeflang, S; Nakajo, I; Smulders, R; Taniuchi, Y; Zhang, W | 1 |
| Lajara, R | 1 |
| Katakami, N; Matsuoka, TA; Shimomura, I; Shiraiwa, T; Takahara, M | 1 |
| Fung, A; Gilbert, RE; Januszewicz, A; Kline, I; Meininger, G; Vijapurkar, U; Weir, MR | 1 |
| Boyle, LD; Wilding, JP | 1 |
| Vallon, V | 1 |
| Bernard, A; Devineni, D; Mamidi, RN; Manitpisitkul, P; Rothenberg, P; Sha, S; Skee, D; Stieltjes, H; Tian, H; Vaccaro, N; Weiner, S | 1 |
| Ishikawa, H; Kashiwagi, A; Kazuta, K; Takahashi, H; Ueyama, E; Utsuno, A; Yoshida, S | 1 |
| Buysman, EK; Chow, W; Henk, HJ; Rupnow, MF | 1 |
| Broedl, UC; Burns, KD; Cherney, DZ; Johansen, OE; Perkins, BA; Soleymanlou, N; von Eynatten, M; Woerle, HJ; Xiao, F; Zimpelmann, J | 1 |
| Ariyawansa, J; Curtin, C; Devineni, D; Di Prospero, NA; Mamidi, RN; Murphy, J; Rothenberg, P; Stieltjes, H; Vaccaro, N; Wajs, E; Wang, SS; Weiner, S | 1 |
| Davidson, JA; Kuritzky, L | 1 |
| Farrell, K; Ghosh, A; Natarajan, J; Pinheiro, J; Plum-Mörschel, L; Polidori, D; Rothenberg, P; Sha, S; Vaccaro, N | 1 |
| Kinoshita, S; Kondo, K | 1 |
| Kihara, Y; Nakano, Y; Sairaku, A | 1 |
| Alba, M; Capuano, G; de Zeeuw, D; Desai, M; Fulcher, G; Jiang, J; Mahaffey, KW; Matthews, D; Meininger, G; Neal, B; Perkovic, V; Shaw, W; Vercruysse, F; Ways, K | 1 |
| Cherney, DZ; Škrtić, M | 1 |
| Al-Rashood, KA; Asiri, YA; Ezzeldin, E; Iqbal, M; Rezk, NL | 1 |
| Bode, B; Fung, A; Harris, S; Meininger, G; Stenlöf, K; Sullivan, D; Usiskin, K | 1 |
| Devineni, D; Polidori, D; Stieltjes, H; Vaccaro, N; Wajs, E | 1 |
| Okada, J; Okada, S; Saito, T; Satoh, T; Shibusawa, R; Shimoda, Y; Tagaya, Y; Yamada, E; Yamada, M | 1 |
| Devineni, D; Murphy, J; Stieltjes, H; Wajs, E; Wang, SS | 1 |
| Mehr, SR; Zimmerman, MP | 1 |
| Davis, SN; Hedrington, MS | 1 |
| Miller, SA; Powell, J; Taylor, JR | 1 |
| Hayashizaki-Someya, Y; Koide, K; Kurosaki, E; Mitori, H; Takakura, S; Takasu, T; Yamazaki, S | 1 |
| Bakris, GL; Majewski, C | 1 |
| Bailey, RA; Blonde, L; Meininger, GE; Rupnow, MF; Vijapurkar, U | 1 |
| Kaku, S; Takakura, S; Takasu, T | 1 |
| Rupprecht, H | 1 |
| Bailey, RA; Blonde, L; Meininger, G; Rupnow, MF; Vijapurkar, U | 1 |
| Dutta, D; Kalra, S | 1 |
| Kırat, T; Köse, N | 1 |
| Curtin, CR; Devineni, D; Murphy, J; Polidori, D; Stieltjes, H; Wajs, E; Wang, SS | 1 |
| Chen, X; Curtin, CR; Devineni, D; Hu, P; Polidori, D; Sha, S; Stieltjes, H; Vaccaro, N; Weiner, S | 1 |
| Ito, Y; Kobuchi, S; Sakaeda, T; Yano, K | 1 |
| Dohi, K; Fujii, E; Fujimoto, N; Ito, M; Moriwaki, K; Nakamori, S; Omori, T; Sato, Y; Takeuchi, T; Yamada, N | 1 |
| Imamura, M; Kurosaki, E; Tahara, A; Takasu, T; Yokono, M | 3 |
| Jia, Y; Lee, JH; Lee, SJ; Seo, WD; Wu, C | 1 |
| Hayashi, A; Kawai, S; Shichiri, M; Takano, K | 1 |
| Fujita, K; Honda, Y; Imajo, K; Kato, S; Kato, T; Kessoku, T; Mawatari, H; Nakajima, A; Ogawa, Y; Saito, S; Tomeno, W; Yoneda, M | 1 |
| Nakamura, I; Sugamori, H; Terauchi, Y; Yokote, K | 2 |
| Hayashizaki, Y; Takakura, S; Takasu, T; Toyoshi, T | 1 |
| Isogawa, A; Ohki, T; Tagawa, K; Toda, N | 1 |
| Furuke, S; Kanno, K; Komiya, C; Miyachi, Y; Ogawa, Y; Shiba, K; Shimazu, N; Tsuchiya, K; Yamaguchi, S | 1 |
| Aihara, Y; Asada, K; Douhara, A; Kawaratani, H; Kitade, M; Moriya, K; Namisaki, T; Nishimura, N; Noguchi, R; Okura, Y; Takeda, K; Yoshiji, H | 1 |
| Atsumi, T; Ichiyama, M; Kameda, R; Miyoshi, H; Nakamura, A; Nomoto, H; Ono, K; Sugawara, H; Yamamoto, C; Yamamoto, K | 1 |
| Hirate, M; Kutoh, E; Murayama, T; Wada, A | 2 |
| Kashiwagi, A; Kawamuki, K; Kazuta, K; Kosakai, Y; Nakamura, I; Satomi, H; Takahashi, H; Ueyama, E; Yoshida, S | 1 |
| Hoshi, H; Niijima, Y; Okada, S; Ono, K; Osaki, A; Saito, T; Yamada, E; Yamada, M | 1 |
| Bando, H; Horasawa, S; Kawasumi, K; Ohashi, K; Osame, K; Saito, S | 1 |
| Nakamura, M; Nishio, D; Saito-Sasaki, N; Sawada, Y | 1 |
| Abiko, A; Atageldiyeva, K; Fujita, Y; Haneda, M; Honjo, J; Makino, Y; Mizumoto, K; Takeda, Y; Takiyama, Y; Yanagimachi, T | 1 |
| Cha, BS; Chuang, LM; Kokubo, S; Lu, CH; Min, KW; Yoshida, S | 1 |
| Harada, M; Kawamura, T; Miyazaki, Y; Nakayama, I; Ogura, M; Okonogi, H; Sato, H; Tokoro, K; Tsuboi, N; Yokoo, T | 1 |
| Asahina, S; Ishihara, H; Nakao, I; Okitsu, A; Yamaguchi, S | 1 |
| Maegawa, H; Nakamura, I; Tabuchi, H; Tobe, K | 1 |
| Dicembrini, I; Mannucci, E; Monami, M | 1 |
| Bailey, RA; Blonde, L; Meininger, G; Patel, CA; Vijapurkar, U | 1 |
| Akhtar, M; Madaan, T; Najmi, AK | 1 |
| Ebihara, K; Ishibashi, S; Kotani, K; Okada, K; Yamazaki, H | 1 |
| Eguchi, K; Higashi, Y; Inoue, T; Ishizu, T; Kadokami, T; Kario, K; Kitakaze, M; Kodera, S; Maemura, K; Matsuhisa, M; Murohara, T; Nanasato, M; Nishio, Y; Node, K; Ohishi, M; Oyama, J; Sata, M; Sato, Y; Shimabukuro, M; Suzuki, M; Taguchi, I; Tanaka, A; Teragawa, H; Tomiyama, H; Ueda, S; Yamada, H | 1 |
| Del Gobbo, LC; Li, Y; Song, Y; Tang, H; Zhai, S; Zhang, J; Zhang, X | 1 |
| Emoto, N; Hattori, N; Nagamine, T; Nakamura, Y; Okajima, F; Sugihara, H | 1 |
| Hamada, K; Takakura, S; Takasu, T | 1 |
| Kato, H; Nagai, Y; Ohta, A; Sada, Y; Tanaka, Y | 1 |
| Liu, P; Mao, S; Rao, M; Shi, Q; Wang, S; Wei, T; Yin, Z; Zhang, L; Zhang, Z; Zhao, B | 1 |
| Atsumi, T; Miyoshi, H; Nakamura, A; Takase, T; Yamamoto, C | 1 |
| Kutoh, E; Murayama, T; Takizawa, Y; Wada, A | 1 |
| Imai, J; Katagiri, H; Kawana, Y; Sawada, S; Yamada, T | 1 |
| Kajiya, S; Kawasoe, M; Kawasoe, S; Kubozono, T; Maruguchi, Y; Miyata, M; Ohishi, M; Uenomachi, H | 1 |
| Amino, N; Hayashizaki, Y; Hirosumi, J; Kurosaki, E; Minoura, H; Takakura, S; Takasu, T | 1 |
| Hashimoto, N; Horikoshi, T; Ishikawa, K; Ishikawa, T; Kobayashi, K; Koshizaka, M; Kuribayashi, N; Nagashima, K; Sato, Y; Shimofusa, R; Takahashi, S; Takemoto, M; Tatsuno, I; Terano, T; Uchida, D; Yokote, K | 1 |
| Gao, HK; Kengne, AP; Mazidi, M; Rezaie, P | 1 |
| Abreu, SC; Alves, SM; Bezerra, MM; Chaves, HV; Cristino-Filho, G; de Castro Brito, GA; de Paulo Teixeira Pinto, V; do Val, DR; Freitas, RS; Gomes, FIF; Lemos, JC; Pereira, KMA | 1 |
| Ishida, H; Nakamoto, S; Osonoi, T; Osonoi, Y; Saito, M; Tamasawa, A | 1 |
| Fukagawa, M; Miyauchi, M; Toyoda, M | 1 |
| Hosoyamada, M; Ishizawa, K; Kuribayashi-Okuma, E; Shibata, S; Toyoki, D; Uchida, S; Xu, N | 1 |
| Akiyama, Y; Inoue, K; Inukai, K; Ito, D; Morimoto, Y; Noda, M; Saito, D; Shimada, A; Shimizu, S; Yanagisawa, M | 1 |
| Ishii, S; Kato, H; Nagai, Y; Nakagawa, T; Nakamura, Y; Ohta, A; Sasaki, Y; Tanaka, Y | 1 |
| Takeishi, S; Takekoshi, S; Tsuboi, H | 1 |
| Fujimori, T; Ichikawa, K; Irahara, A; Kimata, K; Koketsu, Y; Nakano, A; Senda, E; Sumida, Y; Takata, E; Takeda, A; Yamada, H | 1 |
| Iuchi, H; Kayama, Y; Matsutani, D; Minamisawa, S; Sakamoto, M; Suzuki, H; Takeda, N; Utsunomiya, K | 1 |
| Fushimi, Y; Hirukawa, H; Kaku, K; Kamei, S; Kaneto, H; Kimura, T; Kinoshita, T; Kohara, K; Mune, T; Nakanishi, S; Nishioka, M; Obata, A; Okauchi, S; Sanada, J; Shimoda, M; Tatsumi, F | 1 |
| Maegawa, H; Nakamura, I; Tabuchi, H; Tobe, K; Uno, S | 4 |
| Čalija, BR; Cekić, ND; Dobričić, VD; Ilić, TM; Lukić, MŽ; Pajić, NZB; Savić, SD; Todosijević, MN; Vučen, SR; Vuleta, GM | 1 |
| Kanasaki, K; Kitada, M; Koya, D; Li, J; Nitta, K; Takagaki, Y; Takagi, S; Takasu, T | 1 |
| Tahara, A; Takasu, T | 4 |
| Chang, WX; Kumagai, T; Shibata, S; Tamura, Y; Uchida, S | 1 |
| Dobashi, S; Fujii, T; Hashimoto, H; Hisatake, S; Ikeda, T; Kabuki, T; Kiuchi, S; Oka, T | 1 |
| Fukuda, T; Fukui, M; Fushimura, Y; Ikeda, K; Kamezaki, M; Kirita, Y; Kitani, T; Komaki, K; Kusaba, T; Matoba, S; Sakai, R; Shiotsu, Y; Tamagaki, K; Uehara, M; Watanabe, N; Yamashita, N; Yamazaki, M | 1 |
| Takakura, S; Takasu, T | 3 |
| Fukuda, K; Imai, T; Koepsell, H; Masuda, T; Muto, S; Nagata, D; Ohara, K; Onishi, A; Vallon, V; Watanabe, M; Watanabe, Y | 1 |
| Fujimura, Y; Fukuda, T; Horikawa, T; Motonaga, R; Nomiyama, T; Ohsako, T; Shimono, D; Tanabe, M; Terawaki, Y; Yanase, T | 1 |
| Akiyama, N; Kashiwagi, A; Kazuta, K; Kosakai, Y; Nakamura, I; Sakatani, T; Takahashi, H; Ueyama, E | 1 |
| Baik, S; Cha, BS; Chon, S; Chung, CH; Han, KA; Jung, CH; Kim, DS; Lee, IK; Lee, KW; Lee, MK; Lim, S; Park, KS; Park, S; Sakatani, T; Yoon, KH | 1 |
| Azuma, K; Iizuka, T; Inoue, K; Maruyama, S; Matsuzawa, Y; Mukai, S; Nakai, K; Nishikawa, T; Omura, M; Saito, J; Tsurutani, Y | 1 |
| Abdelazeim, B; Abdelazeim, N; El Ashal, G; Elgebaly, A; Mattar, O; Namous, L; Nasreldin, N | 1 |
| Fukuzawa, K; Haruna, M; Hayakawa, T; Hayase, T; Ito, Y; Kobuchi, S; Nakayama, H; Sakaeda, T; Sugano, A; Takahata, N; Takaoka, Y; Tohkin, M; Yoshioka, R | 1 |
| Kondo, Y; Tahara, A; Takasu, T; Tomiyama, H | 1 |
| Higashijima, Y; Inagi, R; Nangaku, M; Saito, H; Suematsu, M; Sugahara, M; Sugiura, Y; Tanaka, S; Tanaka, T; Yamaguchi, J | 1 |
| Aoki, S; Atsumi, T; Cho, KY; Ito, YM; Kurihara, Y; Manda, N; Miya, A; Miyoshi, A; Miyoshi, H; Nakamura, A; Niwa, H; Nomoto, H; Takahashi, K; Yamamoto, C | 1 |
| Komiya, C; Miyachi, Y; Mori, K; Ogasawara, N; Ogawa, Y; Shiba, K; Tsuchiya, K | 1 |
| Orlova, VL; Shestakova, MV; Tretter, R; Verbovoy, AF; Wilding, JPH; Wilpshaar, W | 1 |
| Arima, H; Fuse, K; Ida, S; Inoue, H; Kondo, K; Maegawa, H; Miura, K; Miyazawa, I; Morino, K; Murata, K; Ohashi, N; Sato, D; Sekine, O; Tanaka-Mizuno, S; Ugi, S; Yoshimura, M | 1 |
| Hara, K; Hirota, Y; Kishi, M; Komada, H; Kuroki, Y; Matsuda, T; Miura, H; Ogawa, W; Ohara, T; Okada, Y; Otowa-Suematsu, N; Sakaguchi, K; So, A; Takeda, A; Tamori, Y; Yamada, T; Yokota, K | 1 |
| Fujii, S; Fujiwara, H; Gunji, R; Kakiuchi, S; Kaku, K; Kameda, H; Kurihara, Y; Senda, M; Tamura, M; Utsunomiya, K | 1 |
| Maegawa, H; Nakamura, I; Tobe, K; Uno, S | 3 |
| Aubrey-Bassler, K; Chibrikov, E; Curnew, D; Donnan, JR; Gamble, JM; Grandy, CA; Hache, J; Johnston, K; Marra, CA; Nguyen, H; Swab, M | 1 |
| Isaka, H; Kaku, K; Sakatani, T; Toyoshima, J | 3 |
| Tahara, A; Takakura, S; Takasu, T; Yokono, M | 1 |
| Baba, Y; Hashimoto, N; Hattori, A; Horikoshi, T; Ide, K; Ide, S; Ishibashi, R; Ishikawa, K; Ishikawa, T; Kitamoto, T; Kobayashi, A; Kobayashi, K; Koshizaka, M; Maezawa, Y; Nagashima, K; Nakamura, S; Newby, LK; Ogino, J; Ohara, E; Onishi, S; Sakamoto, K; Sato, Y; Shimada, F; Shimofusa, R; Shoji, M; Takahashi, S; Takemoto, M; Tokuyama, H; Uchida, D; Yamaga, M; Yokoh, H; Yokote, K | 2 |
| Kitamura, K; Miyachi, Y; Mori, K; Nakamura, S; Ogawa, Y; Shiba, K; Tsuchiya, K | 1 |
| Hwang, YC; Kim, JH; Lee, BW; Lee, WJ | 1 |
| Ito, K; Kashiwagi, Y; Kimura, H; Nagoshi, T; Oi, Y; Tanaka, TD; Tanaka, Y; Yoshii, A; Yoshimura, M; Yoshino, T | 1 |
| Atsumi, T; Miyoshi, H; Nakamura, A; Takahashi, K; Takase, T; Yamamoto, C; Yamauchi, Y; Yokota, I | 1 |
| Moradi-Marjaneh, R; Paseban, M; Sahebkar, A | 1 |
| Chen, M; Chen, W; Chen, Y; Li, P; Wang, B; Wang, G | 1 |
| Ishihara, H; Kosakai, Y; Sugitani, T; Yamaguchi, S | 1 |
| Chen, X; Ouyang, J; Wang, H; Yang, J; Yao, G | 1 |
| Fujimura-Tanaka, Y; Hamaguchi, Y; Hamanoue, N; Horikawa, T; Inoue, R; Iwaya, C; Kawanami, D; Kawanami, T; Komatsu, S; Motonaga, R; Nomiyama, T; Numata, T; Tanabe, M; Yanase, T | 1 |
| Fukuda, S; Hosokawa, K; Ida, A; Isomoto, H; Iyama, T; Kanda, T; Koda, M; Mae, Y; Matono, T; Sugihara, T; Takata, T; Taniguchi, S; Yamamoto, M | 1 |
| Nakade, J; Nakamura, M; Okajima, M; Taniguchi, T; Toyama, T | 1 |
| Abe, I; Abe, M; Fujii, H; Kobayashi, K; Kudo, T; Minezaki, M; Mukoubara, S; Ochi, K; Ohe, K; Ohishi, H; Ohnishi, Y; Shinagawa, T; Sugimoto, K; Takashi, Y; Yamao, Y | 1 |
| Fukuda, K; Koepsell, H; Masuda, T; Muto, S; Nagata, D; Ohara, K; Vallon, V; Watanabe, M | 1 |
| Ebihara, K; Ishibashi, S; Nagashima, S; Okada, K; Saito, N; Takahashi, M; Wakabayashi, T | 1 |
| Inoue, T; Kusakabe, T; Odori, S; Satoh-Asahara, N; Shimatsu, A; Tanaka, M; Yamakage, H | 1 |
| Amemiya, H; Asakura, T; Iemitsu, K; Ishikawa, M; Ito, S; Kanamori, A; Kaneshiro, M; Kawata, T; Kubota, A; Machimura, H; Matsuba, I; Matsuzawa, Y; Minagawa, F; Minami, N; Miyakawa, M; Mokubo, A; Shinoda, K; Takai, M; Takeda, H; Takihata, M; Takuma, T; Tanaka, K; Tanaka, Y; Terauchi, Y | 1 |
| Dohi, K; Fujimoto, N; Fukuoka, S; Ishiyama, M; Ito, M; Moriwaki, K; Omori, T; Takeuchi, T | 1 |
| Isaka, H; Kaibara, A; Saito, M; Sakatani, T; Toyoshima, J | 1 |
| Ahmed, MA; Chen, H; Liu, D; Song, F; Wu, H | 1 |
| Mori-Anai, K; Nakada, T; Nakamaru, Y; Saito, R; Takahata, T; Tashima, Y | 1 |
| Kurozumi, A; Okada, Y; Tanaka, Y | 1 |
| Habu, M; Kurozumi, A; Okada, Y; Tanaka, Y | 1 |
| Fujihara, K; Furukawa, K; H Yamada, M; Hatta, M; Ikarashi, T; Iwanaga, M; Katagiri, T; Kitazawa, M; Matsunaga, S; Sone, H; Suzuki, H; Tanaka, S; Yamada, T; Yamamoto, M | 1 |
| Engel, SS; Kadowaki, T; Kaku, K; Kaufman, KD; O'Neill, EA; Okamoto, T; Sato, A; Seino, Y; Shirakawa, M | 2 |
| Bae, J; Cha, BS; Kang, ES; Lee, BW; Lee, JY; Lee, M; Lee, YH; Shin, E | 1 |
| Tahara, A | 2 |
| Inoue, D; Inoue, R; Nangaku, M; Nishi, H | 1 |
| Alkabbani, W; Gamble, JM | 1 |
| Mori, K; Nakamura, S; Ogawa, Y; Okuma, H; Sekine, T; Tsuchiya, K | 1 |
| Fushimi, Y; Kaku, K; Kaneto, H; Katakura, Y; Kimura, T; Kohara, K; Mashiko, A; Mune, T; Nakanishi, S; Obata, A; Sanada, J; Shimoda, M; Tatsumi, F | 1 |
| Aishima, S; Anzai, K; Eguchi, Y; Fujii, H; Hyogo, H; Imajo, K; Isoda, H; Kage, M; Kawaguchi, A; Kawanaka, M; Kessoku, T; Kitajima, Y; Kubotsu, Y; Kurai, O; Nakajima, A; Nakajima, T; Nonaka, M; Oeda, S; Ono, M; Tajiri, R; Takahashi, H; Takamori, A; Tanaka, K; Yoneda, M | 1 |
| Arima, H; Banno, R; Hagiwara, D; Ito, Y; Iwama, S; Kobayashi, T; Mizoguchi, A; Onoue, T; Suga, H; Sugiyama, M; Sun, R; Takagi, H; Taki, K; Tsunekawa, T; Yaginuma, H | 1 |
| Ishihara, H; Kohno, G; Koike, M; Saito, H; Takubo, M; Watanabe, K | 1 |
| Ioannidis, M; Janssens, MH; Mesman, RJ; Revelo, NH; Stempels, FC; Ter Beest, M; van den Bogaart, G | 1 |
| Anno, M; Fujioka, Y; Imamura, T; Ito, Y; Izawa, S; Kato, M; Kitao, S; Matsumoto, K; Matsuzawa, K; Nakamura, R; Okura, H; Okura, T; Shoji, K; Taniguchi, SI; Ueta, E; Yamamoto, K | 1 |
| Fujihara, S; Fujita, K; Haba, R; Himoto, T; Iwama, H; Masaki, T; Morishita, A; Nakahara, M; Nishiyama, A; Okano, K; Ono, M; Oura, K; Shi, T; Tadokoro, T; Takuma, K; Tani, J | 1 |
| Akasaka, H; Fujio, Y; Fukuda, M; Iwakura, K; Kamide, K; Nakatani, S; Ogihara, T; Okamura, A; Rakugi, H; Shintani, A; Sugimoto, K; Takiuchi, S; Taniuchi, S; Yamamoto, K | 1 |
| Anzai, K; Takahashi, H | 1 |
| de Knegt, RJ; van Kleef, LA | 1 |
67 review(s) available for glucose, (beta-d)-isomer and thiophenes
| Article | Year |
|---|---|
A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials.
Topics: Benzhydryl Compounds; Blood Pressure; Body Mass Index; Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Randomized Controlled Trials as Topic; Sodium-Glucose Transport Proteins; Thiophenes | 2012 |
A new approach to glucose control in type 2 diabetes: the role of kidney sodium-glucose co-transporter 2 inhibition.
Topics: Benzhydryl Compounds; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Gluconeogenesis; Glucosides; Homeostasis; Humans; Hypoglycemic Agents; Kidney; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2011 |
[New possibility in the oral glucose lowering treatment of type 2 diabetes mellitus: sodium-glucose co-transporter-2 inhibitors].
Topics: Administration, Oral; Benzhydryl Compounds; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Phlorhizin; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2012 |
Sodium glucose cotransporter 2 and the diabetic kidney.
Topics: Animals; Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus; Diabetic Nephropathies; Glucose; Glucosides; Humans; Hypoglycemic Agents; Kidney Tubules, Proximal; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2013 |
[Glycosuria with SGLT-2 inhibitors--a new treatment approach for type 2 diabetes mellitus].
Topics: Benzhydryl Compounds; Canagliflozin; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Follow-Up Studies; Glipizide; Glucosides; Glycosuria; Humans; Hypoglycemic Agents; Kidney Tubules, Proximal; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2012 |
Inhibition of the sodium glucose co-transporter-2: its beneficial action and potential combination therapy for type 2 diabetes mellitus.
Topics: Animals; Benzhydryl Compounds; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Inflammation; Insulin Resistance; Kidney; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2013 |
Canagliflozin, a new sodium-glucose cotransporter 2 inhibitor, in the treatment of diabetes.
Topics: Animals; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2013 |
Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data.
Topics: Animals; Diabetes Mellitus, Type 2; Glucose; Glucosides; Humans; Hypoglycemic Agents; Kidney; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2013 |
Canagliflozin , an inhibitor of sodium-glucose cotransporter 2, for the treatment of type 2 diabetes mellitus.
Topics: Aged; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Glucose; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2013 |
Canaglifozin (Invokana) for type 2 diabetes.
Topics: Animals; Canagliflozin; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Glucosides; Humans; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2013 |
Canagliflozin: first global approval.
Topics: Animals; Canagliflozin; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Glucosides; Humans; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2013 |
The clinical efficacy and safety of sodium glucose cotransporter-2 inhibitors in adults with type 2 diabetes mellitus.
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Humans; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2013 |
Review of insulin-dependent and insulin-independent agents for treating patients with type 2 diabetes mellitus and potential role for sodium-glucose co-transporter 2 inhibitors.
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Insulin; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2013 |
Canagliflozin for the treatment of type 2 diabetes.
Topics: Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Glucosides; Humans; Insulin-Secreting Cells; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2013 |
The role of kidney in glucose homeostasis--SGLT2 inhibitors, a new approach in diabetes treatment.
Topics: Animals; Benzhydryl Compounds; Canagliflozin; Clinical Trials as Topic; Diabetes Mellitus; Gluconeogenesis; Glucose; Glucosides; Homeostasis; Humans; Hypoglycemic Agents; Kidney; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome | 2013 |
Sodium glucose co-transporter 2 (SGLT2) inhibition with canagliflozin in type 2 diabetes mellitus.
Topics: Canagliflozin; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; United States | 2013 |
Type 2 diabetes mellitus and Invokana: an FDA approved drug.
Topics: Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Drug Approval; Female; Glucosides; Humans; Hypoglycemic Agents; India; Life Style; Male; Obesity; Thiophenes; United States; United States Food and Drug Administration | 2013 |
Canagliflozin: Improving diabetes by making urine sweet.
Topics: Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Disease Progression; Glucosides; Humans; Hypoglycemic Agents; Thiophenes; Treatment Outcome; Urinalysis | 2013 |
Sodium-glucose linked transporter-2 inhibitors: potential for renoprotection beyond blood glucose lowering?
Topics: Animals; Benzhydryl Compounds; Blood Pressure; Canagliflozin; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glomerular Filtration Rate; Glucose; Glucosides; Humans; Hypoglycemic Agents; Kidney Glomerulus; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Uric Acid | 2014 |
Canagliflozin, a novel SGLT2 inhibitor for treatment of type 2 diabetes.
Topics: Animals; Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2013 |
Canagliflozin: a novel treatment option for type 2 diabetes.
Topics: Animals; Biomarkers; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Drug Design; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Kidney; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome | 2013 |
Canagliflozin: a new hope in the antidiabetic armamentarium.
Topics: Canagliflozin; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2013 |
Evaluating SGLT2 inhibitors for type 2 diabetes: pharmacokinetic and toxicological considerations.
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Interactions; Glucosides; Hepatic Insufficiency; Humans; Hypoglycemic Agents; Membrane Transport Modulators; Renal Insufficiency; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2014 |
[Sodium-glucose co-transporter-2 inhibitors: from the bark of apple trees and familial renal glycosuria to the treatment of type 2 diabetes mellitus].
Topics: Adsorption; Animals; Benzhydryl Compounds; Biological Transport, Active; Canagliflozin; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Drugs, Investigational; Glucose; Glucosides; Glycosides; Glycosuria; Glycosuria, Renal; Humans; Hypoglycemic Agents; Kidney Tubules, Proximal; Malus; Phlorhizin; Phytotherapy; Plant Bark; Rats; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome | 2013 |
[SGLT-2 inhibition with canagliflozin: a new option for the treatment of type 2 diabetes].
Topics: Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dose-Response Relationship, Drug; Double-Blind Method; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Kidney; Kidney Concentrating Ability; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2014 |
[Canagliflozin monotherapy: clinical study data in type 2 diabetes mellitus].
Topics: Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2014 |
[Oral add-on therapy to metformin in type 2 diabetes mellitus: a direct comparison beween canagliflozin and glimepiride].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Canagliflozin; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Endpoint Determination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Intra-Abdominal Fat; Male; Metformin; Middle Aged; Randomized Controlled Trials as Topic; Sulfonylurea Compounds; Thiophenes | 2014 |
[Oral add-on therapy to metformin in type 2 diabetes mellitus: a direct comparison between canagliflozin and sitagliptin].
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dose-Response Relationship, Drug; Drug Therapy, Combination; Endpoint Determination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Thiophenes; Triazoles; Young Adult | 2014 |
Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors.
Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Glucosides; Humans; Hypoglycemic Agents; Kidney; Renal Reabsorption; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2014 |
Ramping glucosuria for management of type 2 diabetes mellitus: an emerging cynosure.
Topics: Benzhydryl Compounds; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Female; Glucosides; Glycemic Index; Glycosuria; Humans; Hypoglycemic Agents; Male; Severity of Illness Index; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome | 2014 |
Effect of canagliflozin on serum electrolytes in patients with type 2 diabetes in relation to estimated glomerular filtration rate (eGFR).
Topics: Adult; Aged; Biomarkers; Canagliflozin; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Electrolytes; Female; Glomerular Filtration Rate; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Water-Electrolyte Imbalance | 2014 |
Canagliflozin: a review of its use in patients with type 2 diabetes mellitus.
Topics: Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Molecular Structure; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2014 |
A review of the efficacy and safety of canagliflozin in elderly patients with type 2 diabetes.
Topics: Aged; Canagliflozin; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Interactions; Glucosides; Glycated Hemoglobin; Humans; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2014 |
Clinical implication of SGLT2 inhibitors in type 2 diabetes.
Topics: Administration, Oral; Benzhydryl Compounds; Canagliflozin; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Glucose; Glucosides; Humans; Hypoglycemic Agents; Insulin; Kidney; Molecular Structure; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Sorbitol; Thiophenes | 2014 |
Combinational therapy with metformin and sodium-glucose cotransporter inhibitors in management of type 2 diabetes: systematic review and meta-analyses.
Topics: Adult; Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2014 |
Efficacy and safety of canagliflozin in subjects with type 2 diabetes: systematic review and meta-analysis.
Topics: Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2014 |
The effects of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes: protocol for a systematic review with meta-analysis of randomised trials.
Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Mass Index; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Insulin Resistance; Randomized Controlled Trials as Topic; Renal Elimination; Sodium-Glucose Transporter 2 Inhibitors; Systematic Reviews as Topic; Thiophenes; Treatment Outcome | 2014 |
Update on developments with SGLT2 inhibitors in the management of type 2 diabetes.
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2014 |
Canagliflozin, a sodium glucose co-transporter 2 inhibitor, for the management of type 2 diabetes.
Topics: Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemic Agents; Kidney; Lipids; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2014 |
Clinical pharmacokinetics and pharmacodynamics of the novel SGLT2 inhibitor ipragliflozin.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Japan; Male; Middle Aged; Renal Insufficiency; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2014 |
The potential role of sodium glucose co-transporter 2 inhibitors in combination therapy for type 2 diabetes mellitus.
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucose; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Practice Guidelines as Topic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2014 |
A safety evaluation of canagliflozin : a first-in-class treatment for type 2 diabetes.
Topics: Animals; Biomarkers; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Kidney Tubules; Risk Assessment; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome | 2014 |
The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus.
Topics: Benzhydryl Compounds; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Kidney; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2015 |
Sodium glucose co-transporter 2 inhibitors and their mechanism for improving glycemia in patients with type 2 diabetes.
Topics: Benzhydryl Compounds; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Glycosuria; Homeostasis; Humans; Hypoglycemic Agents; Kidney; Renal Reabsorption; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2014 |
Invokamet and Xigduo XR: two new combinations for type 2 diabetes.
Topics: Benzhydryl Compounds; Canagliflozin; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Drug Approval; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transport Proteins; Thiophenes; United States | 2014 |
Sodium-glucose cotransporter-2 inhibition and the potential for renal protection in diabetic nephropathy.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glomerular Filtration Rate; Glucosides; Humans; Hypoglycemic Agents; Kidney Tubules, Proximal; Renal Reabsorption; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Sodium, Dietary; Thiophenes | 2015 |
Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2015 |
Ipragliflozin , a sodium-glucose cotransporter 2 inhibitor, in the treatment of type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Drug Interactions; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Weight Loss | 2015 |
Sodium-glucose cotransporter 2 inhibitors: the new option for diabetes mellitus management.
Topics: Benzhydryl Compounds; Canagliflozin; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Evidence-Based Medicine; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Randomized Controlled Trials as Topic; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome | 2015 |
Use of sodium-glucose cotransporter type 2 inhibitors in older adults with type 2 diabetes mellitus.
Topics: Aged; Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Evidence-Based Medicine; Glucosides; Humans; Hypoglycemic Agents; Meta-Analysis as Topic; Randomized Controlled Trials as Topic; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome; Weight Loss | 2015 |
[Pharmacological and clinical profile of ipragliflozin (Suglat®): a new therapeutic agent for type 2 diabetes].
Topics: Animals; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Design; Glucosides; Humans; Insulin-Secreting Cells; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2015 |
[The role of SGLT-2 inhibitors in the treatment of type 2 diabetes].
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2015 |
Diabetes-Related Composite Quality End Point Attainment: Canagliflozin Versus Sitagliptin Based on a Pooled Analysis of 2 Clinical Trials.
Topics: Blood Pressure; Body Mass Index; Canagliflozin; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Pyrazines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Thiophenes; Triazoles | 2015 |
[Canagliflozin (Invokana): kidney SGLT2 cotransporter inhibitor for treating type 2 diabetes].
Topics: Canagliflozin; Diabetes Mellitus, Type 2; Glucose; Glucosides; Humans; Hypoglycemic Agents; Kidney; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2014 |
Pharmacokinetics, Pharmacodynamics and Clinical Use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease.
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2015 |
First case of drug eruption due to ipragliflozin: Case report and review of the literature.
Topics: Aged; Diabetes Mellitus; Drug Eruptions; Glucosides; Humans; Hypoglycemic Agents; Male; Thiophenes | 2017 |
Effects of SGLT-2 inhibitors on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trials.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2017 |
Sodium glucose CoTransporter 2 (SGLT2) inhibitors: Current status and future perspective.
Topics: Animals; Benzhydryl Compounds; Glucose; Glucosides; Humans; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2016 |
Elevated serum magnesium associated with SGLT2 inhibitor use in type 2 diabetes patients: a meta-analysis of randomised controlled trials.
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Magnesium; Male; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2016 |
Effect of Sodium-Glucose Cotransport-2 Inhibitors on Blood Pressure in People With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of 43 Randomized Control Trials With 22 528 Patients.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Biomarkers; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Kidney Tubules, Proximal; Lipids; Male; Middle Aged; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome; Young Adult | 2017 |
Time to Target Uric Acid to Retard Chronic Kidney Disease Progression.
Topics: Allopurinol; Animals; Anion Transport Proteins; ATP Binding Cassette Transporter, Subfamily G, Member 2; Disease Progression; Enzyme Inhibitors; Febuxostat; Glucosides; Gout Suppressants; Humans; Hyperuricemia; Monosaccharide Transport Proteins; Nitriles; Oxidative Stress; Pyridines; Renal Insufficiency, Chronic; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Uric Acid; Xanthine Oxidase | 2018 |
Tolerability and Efficacy of Ipragliflozin in The Management of Inadequately Controlled Type 2 Diabetes mellitus: A Systematic Review and Meta-analysis.
Topics: Diabetes Mellitus, Type 2; Glucosides; Humans; Outcome Assessment, Health Care; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2021 |
Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis.
Topics: Acute Kidney Injury; Amputation, Surgical; Benzhydryl Compounds; Canagliflozin; Diabetic Ketoacidosis; Fractures, Bone; Glucosides; Humans; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Urinary Tract Infections | 2019 |
Natural products with SGLT2 inhibitory activity: Possibilities of application for the treatment of diabetes.
Topics: Benzhydryl Compounds; Biological Products; Canagliflozin; Diabetes Mellitus; Glucosides; Humans; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2019 |
Efficacy and safety of ipragliflozin as add-on to metformin for type 2 diabetes: a meta-analysis of double-blind randomized controlled trials.
Topics: Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Randomized Controlled Trials as Topic; Thiophenes | 2019 |
Adverse Drug Events Observed with the Novel Sodium/Glucose Co-Transporter 2 Inhibitor Ipragliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Studies.
Topics: Diabetes Mellitus, Type 2; Drug-Related Side Effects and Adverse Reactions; Glucosides; Humans; Pharmaceutical Preparations; Sodium; Sodium-Glucose Transporter 2 Inhibitors; Symporters; Thiophenes | 2020 |
Profile of Ipragliflozin, an Oral SGLT-2 Inhibitor for the Treatment of Type 2 Diabetes: The Evidence to Date.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2021 |
86 trial(s) available for glucose, (beta-d)-isomer and thiophenes
| Article | Year |
|---|---|
Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects.
Topics: Adolescent; Adult; Canagliflozin; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Glucosides; Glycosuria; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Young Adult | 2011 |
Safety, pharmacokinetic, and pharmacodynamic profiles of ipragliflozin (ASP1941), a novel and selective inhibitor of sodium-dependent glucose co-transporter 2, in patients with type 2 diabetes mellitus.
Topics: Adolescent; Adult; Aged; Area Under Curve; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Fructosamine; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Young Adult | 2011 |
Effect of Ipragliflozin (ASP1941), a novel selective sodium-dependent glucose co-transporter 2 inhibitor, on urinary glucose excretion in healthy subjects.
Topics: Adult; Blood Glucose; Blood Pressure Determination; Body Mass Index; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; Female; Glucose; Glucosides; Glycosuria; Heart Rate; Humans; Hyperglycemia; Hypoglycemic Agents; Male; Middle Aged; Placebos; Sex Factors; Sodium-Glucose Transporter 2 Inhibitors; Symporters; Thiophenes; Young Adult | 2011 |
Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin.
Topics: Adolescent; Adult; Aged; Blood Glucose; Canagliflozin; Cohort Studies; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Female; Glucosides; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Thiophenes; Time Factors; Treatment Outcome; Young Adult | 2012 |
Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes.
Topics: Adolescent; Adult; Aged; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome; Weight Loss; Young Adult | 2012 |
Effect of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, on bacteriuria and urinary tract infection in subjects with type 2 diabetes enrolled in a 12-week, phase 2 study.
Topics: Bacteriuria; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Glycosuria; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Triazoles; Urinary Tract Infections | 2012 |
No pharmacokinetic interaction between ipragliflozin and sitagliptin, pioglitazone, or glimepiride in healthy subjects.
Topics: Adolescent; Adult; Area Under Curve; Body Mass Index; Cross-Over Studies; Diabetes Mellitus, Type 2; Drug Interactions; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Thiophenes; Triazoles | 2012 |
Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor.
Topics: Antifungal Agents; Blood Glucose; Canagliflozin; Candida; Candidiasis, Vulvovaginal; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Middle Aged; Pyrazines; Sitagliptin Phosphate; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Triazoles; Vagina | 2012 |
Combination treatment with ipragliflozin and metformin: a randomized, double-blind, placebo-controlled study in patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Area Under Curve; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; Europe; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Metabolic Clearance Rate; Metformin; Middle Aged; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Time Factors; Treatment Outcome | 2012 |
Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: a dose-finding study.
Topics: Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Europe; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Thiophenes; Time Factors; Treatment Outcome; United States | 2013 |
Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Canagliflozin; Cholesterol, HDL; Diabetes Mellitus, Type 2; Diet; Double-Blind Method; Exercise; Fasting; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Postprandial Period; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome; Triglycerides; Weight Loss | 2013 |
Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study.
Topics: Acetaminophen; Adolescent; Adult; Blood Glucose; Canagliflozin; Cross-Over Studies; Depression, Chemical; Gastric Emptying; Glucose; Glucosides; Glycosuria; Humans; Insulin; Intestinal Absorption; Male; Placebos; Postprandial Period; Sodium-Glucose Transporter 1; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2013 |
Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease.
Topics: Aged; Biomarkers; Blood Glucose; Body Weight; Canagliflozin; Comorbidity; Diabetes Mellitus, Type 2; Disease Progression; Diuresis; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Glomerular Filtration Rate; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome; Urinary Tract Infections | 2013 |
Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial.
Topics: Aged; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiophenes; Treatment Outcome; Triazoles | 2013 |
Validation of a novel method for determining the renal threshold for glucose excretion in untreated and canagliflozin-treated subjects with type 2 diabetes mellitus.
Topics: Blood Glucose; Body Mass Index; Canagliflozin; Diabetes Mellitus, Type 2; Female; Glomerular Filtration Rate; Glucosides; Glycosuria; Humans; Hyperglycemia; Hypoglycemic Agents; Kidney; Kidney Function Tests; Male; Membrane Transport Modulators; Middle Aged; Overweight; Postprandial Period; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2013 |
Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus.
Topics: Adult; Area Under Curve; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Female; Glucose; Glucosides; Glucuronides; Half-Life; Humans; Hypoglycemic Agents; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2013 |
Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial.
Topics: Age Factors; Aged; Aged, 80 and over; Canagliflozin; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Prospective Studies; Safety; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2013 |
Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, 12-week study.
Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Thiophenes; Treatment Outcome; Young Adult | 2013 |
Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Canagliflozin; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Thiophenes; Treatment Outcome; Young Adult | 2013 |
Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)--a randomized placebo-controlled trial.
Topics: Aged; Biomarkers; Canagliflozin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Electrocardiography; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Research Design; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2013 |
Ipragliflozin does not prolong QTc interval in healthy male and female subjects: a phase I study.
Topics: Adult; Aza Compounds; Black or African American; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Electrocardiography; Female; Fluoroquinolones; Glucosides; Healthy Volunteers; Heart Conduction System; Heart Rate; Humans; Male; Middle Aged; Moxifloxacin; Quinolines; Thiophenes; White People; Young Adult | 2013 |
Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial.
Topics: Adolescent; Aged; Aged, 80 and over; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fasting; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipids; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Thiophenes; Treatment Outcome; Triazoles | 2013 |
Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study.
Topics: Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diet; Double-Blind Method; Exercise; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Middle Aged; Placebos; Pyrazines; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome; Triazoles; Triglycerides; Weight Loss | 2014 |
Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Blood Pressure; Canagliflozin; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin-Secreting Cells; Lipid Metabolism; Male; Metformin; Middle Aged; Sulfonylurea Compounds; Thiophenes; Treatment Outcome; Weight Loss; Young Adult | 2013 |
Canagliflozin: effects in overweight and obese subjects without diabetes mellitus.
Topics: Adult; Anti-Obesity Agents; Blood Pressure; Body Mass Index; Body Weight; Canagliflozin; Dose-Response Relationship, Drug; Double-Blind Method; Female; Glucose; Glucosides; Humans; Male; Middle Aged; Obesity; Overweight; Sodium-Glucose Transport Proteins; Thiophenes; Treatment Outcome | 2014 |
Effect of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, on measurement of serum 1,5-anhydroglucitol.
Topics: Blood Glucose; Canagliflozin; Deoxyglucose; Diabetes Mellitus, Type 2; Double-Blind Method; Follow-Up Studies; Glucosides; Glycated Hemoglobin; Humans; Prognosis; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2014 |
Urinary tract infection in randomized phase III studies of canagliflozin, a sodium glucose co-transporter 2 inhibitor.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incidence; Male; Metformin; Middle Aged; Recurrence; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Thiophenes; Urinary Tract Infections; Young Adult | 2014 |
Attainment of diabetes-related quality measures with canagliflozin versus sitagliptin.
Topics: Aged; Blood Pressure; Body Mass Index; Canagliflozin; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Quality Indicators, Health Care; Racial Groups; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Triazoles | 2014 |
Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies.
Topics: Aged; Canagliflozin; Diabetes Mellitus, Type 2; Female; Genital Diseases, Female; Genital Diseases, Male; Glucosides; Humans; Hypoglycemic Agents; Incidence; Male; Middle Aged; Mycoses; Thiophenes | 2014 |
Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone.
Topics: Blood Glucose; Blood Pressure; Canagliflozin; Candidiasis; Diabetes Mellitus, Type 2; Diuretics, Osmotic; Double-Blind Method; Drug Therapy, Combination; Female; Genital Diseases, Female; Genital Diseases, Male; Glucosides; Humans; Hypoglycemic Agents; Lipids; Male; Metformin; Middle Aged; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Thiophenes; Treatment Outcome; Triazoles; Weight Loss | 2014 |
Metabolism and excretion of canagliflozin in mice, rats, dogs, and humans.
Topics: Administration, Oral; Adult; Animals; Bile; Canagliflozin; Carbon Radioisotopes; Dogs; Feces; Female; Glucosides; Glucuronides; Humans; Hypoglycemic Agents; Magnetic Resonance Spectroscopy; Male; Mice; Middle Aged; Rats; Rats, Sprague-Dawley; Species Specificity; Thiophenes; Tissue Distribution; Young Adult | 2014 |
Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves model-based indices of beta cell function in patients with type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Canagliflozin; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Humans; Insulin-Secreting Cells; Least-Squares Analysis; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Sodium-Glucose Transporter 2; Sulfonylurea Compounds; Thiophenes; Time Factors; Triazoles | 2014 |
Effects of hydrochlorothiazide on the pharmacokinetics, pharmacodynamics, and tolerability of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants.
Topics: Adolescent; Adult; Blood; Canagliflozin; Drug Administration Schedule; Drug Therapy, Combination; Female; Glucosides; Healthy Volunteers; Humans; Hydrochlorothiazide; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Urine; Young Adult | 2014 |
The impact of weight loss on weight-related quality of life and health satisfaction: results from a trial comparing canagliflozin with sitagliptin in triple therapy among people with type 2 diabetes.
Topics: Adult; Age Factors; Aged; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Health Behavior; Humans; Hypoglycemic Agents; Male; Middle Aged; Personal Satisfaction; Pyrazines; Quality of Life; Self Efficacy; Sex Factors; Sexual Behavior; Sitagliptin Phosphate; Thiophenes; Triazoles; Weight Loss | 2014 |
Ipragliflozin in combination with metformin for the treatment of Japanese patients with type 2 diabetes: ILLUMINATE, a randomized, double-blind, placebo-controlled study.
Topics: Aged; Asian People; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Placebos; Thiophenes | 2015 |
Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Antihypertensive Agents; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fasting; Female; Glucosides; Glycated Hemoglobin; Humans; Hypertension; Hypoglycemic Agents; Kidney; Male; Metformin; Middle Aged; Plasma Volume; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome; Water-Electrolyte Balance; Weight Loss | 2014 |
Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease.
Topics: Aged; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Double-Blind Method; Drug Administration Schedule; Female; Glomerular Filtration Rate; Glucosides; Humans; Hypoglycemic Agents; Male; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome | 2014 |
Efficacy and safety of canagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled with diet and exercise: a 24-week, randomized, double-blind, placebo-controlled, Phase III study.
Topics: Aged; Blood Glucose; Blood Pressure; Canagliflozin; Diabetes Mellitus, Type 2; Double-Blind Method; Exercise Therapy; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Japan; Ketone Bodies; Lipids; Male; Middle Aged; Thiophenes; Treatment Outcome; Weight Loss | 2014 |
Canagliflozin, a sodium glucose co-transporter 2 inhibitor, reduces post-meal glucose excursion in patients with type 2 diabetes by a non-renal mechanism: results of a randomized trial.
Topics: Blood Glucose; Canagliflozin; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Fasting; Female; Glucose; Glucosides; Humans; Kidney; Male; Metformin; Middle Aged; Postprandial Period; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2014 |
Pharmacokinetic and pharmacodynamic study of ipragliflozin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study.
Topics: Adult; Aged; Area Under Curve; Asian People; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Thiophenes; Tissue Distribution; Young Adult | 2014 |
Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glomerular Filtration Rate; Glucosides; Humans; Hypoglycemic Agents; Insulin; Kidney; Male; Middle Aged; Thiophenes | 2014 |
Canagliflozin in Asian patients with type 2 diabetes on metformin alone or metformin in combination with sulphonylurea.
Topics: Aged; Canagliflozin; China; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Resistance; Drug Resistance, Multiple; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Malaysia; Male; Membrane Transport Modulators; Metformin; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Thiophenes; Vietnam | 2015 |
Pharmacokinetic and pharmacodynamic profiles of canagliflozin in Japanese patients with type 2 diabetes mellitus and moderate renal impairment.
Topics: Adult; Aged; Area Under Curve; Asian People; Canagliflozin; Cross-Over Studies; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Glucosides; Humans; Hypoglycemic Agents; Japan; Male; Middle Aged; Renal Insufficiency; Thiophenes | 2014 |
Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study.
Topics: Blood Glucose; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sulfonylurea Compounds; Thiophenes; Time Factors; Treatment Outcome; Weight Loss | 2015 |
Effect of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on the pharmacokinetics of oral contraceptives, warfarin, and digoxin in healthy participants.
Topics: Adult; Anticoagulants; Area Under Curve; Blood Coagulation; Canagliflozin; Cardiotonic Agents; Contraceptives, Oral, Combined; Cross-Over Studies; Digoxin; Drug Administration Schedule; Drug Combinations; Drug Dosage Calculations; Drug Interactions; Ethinyl Estradiol; Female; Glucosides; Half-Life; Healthy Volunteers; Humans; Hypoglycemic Agents; International Normalized Ratio; Levonorgestrel; Male; Metabolic Clearance Rate; Middle Aged; Polypharmacy; Risk Assessment; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Warfarin; Young Adult | 2015 |
A randomized, double-blind, placebo-controlled study on long-term efficacy and safety of ipragliflozin treatment in patients with type 2 diabetes mellitus and renal impairment: results of the long-term ASP1941 safety evaluation in patients with type 2 dia
Topics: Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Renal Insufficiency; Thiophenes; Time Factors; Treatment Outcome; Weight Loss | 2015 |
Effects of rifampin, cyclosporine A, and probenecid on the pharmacokinetic profile of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants.
Topics: Adult; Canagliflozin; Cyclosporine; Drug Interactions; Female; Glucosides; Humans; Male; Probenecid; Rifampin; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2015 |
Pharmacodynamic differences between canagliflozin and dapagliflozin: results of a randomized, double-blind, crossover study.
Topics: Adult; Aged; Benzhydryl Compounds; Blood Glucose; Body Weight; Canagliflozin; Cross-Over Studies; Double-Blind Method; Drug Administration Schedule; Female; Glomerular Filtration Rate; Glucose; Glucosides; Humans; Hypoglycemic Agents; Kidney; Male; Middle Aged; Postprandial Period; Thiophenes | 2015 |
Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes.
Topics: Blood Glucose; Blood Pressure; Canagliflozin; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Glucosides; Glycated Hemoglobin; Glycosuria; Humans; Hypoglycemia; Hypoglycemic Agents; Hypovolemia; Insulin; Male; Middle Aged; Mycoses; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome; Urinary Tract Infections; Weight Loss | 2015 |
Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes.
Topics: Aged; Aged, 80 and over; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diuresis; Double-Blind Method; Fasting; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Mycoses; Osmolar Concentration; Thiophenes; Urinary Tract Infections | 2015 |
Single- and multiple-dose pharmacokinetics and pharmacodynamics of canagliflozin, a selective inhibitor of sodium glucose co-transporter 2, in healthy participants.
Topics: Adult; Canagliflozin; Dose-Response Relationship, Drug; Female; Glucosides; Humans; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2015 |
Effect of food on the pharmacokinetics of canagliflozin/metformin (150/1,000 mg) immediate-release fixed-dose combination tablet in healthy participants.
Topics: Administration, Oral; Adolescent; Adult; Area Under Curve; Canagliflozin; Cross-Over Studies; Drug Combinations; Fasting; Female; Food-Drug Interactions; Glucosides; Half-Life; Healthy Volunteers; Humans; Hypoglycemic Agents; Male; Metabolic Clearance Rate; Metformin; Middle Aged; Postprandial Period; Tablets; Therapeutic Equivalency; Thiophenes; Young Adult | 2015 |
Diabetes-related quality measure attainment: canagliflozin versus sitagliptin based on a pooled analysis of 2 clinical trials.
Topics: Blood Pressure; Body Mass Index; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipoproteins, LDL; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Thiophenes; Treatment Outcome; Triazoles | 2014 |
Pharmacokinetics and pharmacodynamics of once- and twice-daily multiple-doses of canagliflozin, a selective inhibitor of sodium glucose co-transporter 2, in healthy participants.
Topics: Administration, Oral; Adult; Area Under Curve; Blood Glucose; Canagliflozin; Cross-Over Studies; Drug Administration Schedule; Drug Monitoring; Female; Glucosides; Half-Life; Healthy Volunteers; Humans; Hypoglycemic Agents; Male; Models, Biological; Risk Assessment; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Young Adult | 2015 |
Pharmacokinetics, Pharmacodynamics, and Safety of Single-Dose Canagliflozin in Healthy Chinese Subjects.
Topics: Adolescent; Adult; Asian People; Blood Glucose; Canagliflozin; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Female; Glomerular Filtration Rate; Glucosides; Glycosuria; Healthy Volunteers; Humans; Hypoglycemic Agents; Kidney; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Young Adult | 2015 |
Ipragliflozin as an Initial Therapy in Drug Naïve Subjects with Type 2 Diabetes.
Topics: Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Piperidines; Prospective Studies; Thiophenes; Uracil | 2016 |
Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes stratified by body mass index: A subgroup analysis of five randomized clinical trials.
Topics: Asian People; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Japan; Male; Metformin; Middle Aged; Pioglitazone; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Thiazolidinediones; Thiophenes; Treatment Outcome | 2016 |
Efficacy, safety, and tolerability of ipragliflozin in Asian patients with type 2 diabetes mellitus and inadequate glycemic control with metformin: Results of a phase 3 randomized, placebo-controlled, double-blind, multicenter trial.
Topics: Asian People; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Humans; Male; Metformin; Thiophenes; Treatment Outcome | 2016 |
Efficacy and safety of ipragliflozin as add-on therapy to insulin in Japanese patients with type 2 diabetes mellitus (IOLITE): a multi-centre, randomized, placebo-controlled, double-blind study.
Topics: Adiponectin; Aged; Asian People; Blood Glucose; Body Weight; C-Peptide; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Fasting; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Japan; Male; Middle Aged; Reproductive Tract Infections; Thiophenes; Treatment Outcome; Urinary Tract Infections | 2016 |
Rationale and design of a multicenter randomized controlled study to evaluate the preventive effect of ipragliflozin on carotid atherosclerosis: the PROTECT study.
Topics: Adult; Aged; Biomarkers; Carotid Artery Diseases; Carotid Artery, Common; Carotid Intima-Media Thickness; Clinical Protocols; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Japan; Male; Middle Aged; Prospective Studies; Research Design; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Time Factors; Treatment Outcome; Young Adult | 2016 |
Preventive effect of ipragliflozin on nocturnal hypoglycemia in patients with type 2 diabetes treated with basal-bolus insulin therapy: An open-label, single-center, parallel, randomized control study.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Middle Aged; Pyrazoles; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiazolidines; Thiophenes; Treatment Outcome; Young Adult | 2017 |
Effect of 24-week treatment with ipragliflozin on proinsulin/C-peptide ratio in Japanese patients with type 2 diabetes.
Topics: Adult; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Female; Glucose; Glucosides; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin-Secreting Cells; Male; Middle Aged; Proinsulin; Prospective Studies; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2017 |
Efficacy and safety of ipragliflozin and metformin for visceral fat reduction in patients with type 2 diabetes receiving treatment with dipeptidyl peptidase-4 inhibitors in Japan: a study protocol for a prospective, multicentre, blinded-endpoint phase IV
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Intra-Abdominal Fat; Japan; Metformin; Prospective Studies; Research Design; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Tomography, X-Ray Computed; Treatment Outcome | 2017 |
Efficacy of ipragliflozin as monotherapy or as add-on therapy with other oral antidiabetic medications for treating type 2 diabetes in Japanese patients with inadequate glycemic control: A subgroup analysis based on patient characteristics.
Topics: Administration, Oral; Aged; Asian People; Blood Glucose; Body Composition; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Japan; Male; Middle Aged; Prospective Studies; Thiophenes; Treatment Outcome; Waist Circumference | 2018 |
Comparison of Ipragliflozin and Pioglitazone Effects on Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Randomized, 24-Week, Open-Label, Active-Controlled Trial.
Topics: Adult; Aged; Blood Glucose; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Pioglitazone; Thiazolidinediones; Thiophenes; Treatment Outcome; Young Adult | 2017 |
Comparison of tofogliflozin 20 mg and ipragliflozin 50 mg used together with insulin glargine 300 U/mL using continuous glucose monitoring (CGM): A randomized crossover study.
Topics: Activities of Daily Living; Aged; Benzhydryl Compounds; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucosides; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Insulin Glargine; Japan; Male; Membrane Transport Modulators; Middle Aged; Monitoring, Ambulatory; Risk; ROC Curve; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2017 |
Efficacy and safety of sodium-glucose cotransporter 2 inhibitor ipragliflozin on glycemic control and cardiovascular parameters in Japanese patients with type 2 diabetes mellitus; Fukuoka Study of Ipragliflozin (FUSION).
Topics: Adiponectin; Adult; Aged; Blood Glucose; Body Mass Index; C-Peptide; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome; Young Adult | 2018 |
Improved cardiometabolic risk factors in Japanese patients with type 2 diabetes treated with ipragliflozin: a pooled analysis of six randomized, placebo-controlled trials.
Topics: Aged; Blood Glucose; Body Mass Index; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Japan; Male; Middle Aged; Risk Factors; Thiophenes; Treatment Outcome | 2018 |
Efficacy and safety of ipragliflozin as an add-on therapy to sitagliptin and metformin in Korean patients with inadequately controlled type 2 diabetes mellitus: A randomized controlled trial.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Male; Metformin; Middle Aged; Republic of Korea; Sitagliptin Phosphate; Thiophenes; Treatment Outcome; Young Adult | 2018 |
Comparative study of the effects of ipragliflozin and sitagliptin on multiple metabolic variables in Japanese patients with type 2 diabetes: A multicentre, randomized, prospective, open-label, active-controlled study.
Topics: Adult; Aged; Asian People; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Japan; Male; Middle Aged; Sitagliptin Phosphate; Thiophenes | 2018 |
A phase 3 randomized placebo-controlled trial to assess the efficacy and safety of ipragliflozin as an add-on therapy to metformin in Russian patients with inadequately controlled type 2 diabetes mellitus.
Topics: Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Russia; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome | 2018 |
Ipragliflozin, a sodium-glucose cotransporter 2 inhibitor, reduces bodyweight and fat mass, but not muscle mass, in Japanese type 2 diabetes patients treated with insulin: A randomized clinical trial.
Topics: Adipose Tissue; Adult; Aged; Biomarkers; Body Composition; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studies; Glucosides; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Muscle, Skeletal; Prognosis; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Young Adult | 2019 |
Clinical pharmacology study of ipragliflozin in Japanese patients with type 1 diabetes mellitus: A phase 2, randomized, placebo-controlled trial.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 1; Dose-Response Relationship, Drug; Female; Glucosides; Glycosuria; Humans; Japan; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Young Adult | 2019 |
Comparing the effects of ipragliflozin versus metformin on visceral fat reduction and metabolic dysfunction in Japanese patients with type 2 diabetes treated with sitagliptin: A prospective, multicentre, open-label, blinded-endpoint, randomized controlled
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Intra-Abdominal Fat; Japan; Male; Metformin; Middle Aged; Prospective Studies; Single-Blind Method; Sitagliptin Phosphate; Thiophenes; Treatment Outcome | 2019 |
Efficacy and safety of ipragliflozin add-on therapy to insulin in Japanese patients with type 1 diabetes mellitus: A randomized, double-blind, phase 3 trial.
Topics: Adult; Body Weight; Diabetes Mellitus, Type 1; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Japan; Male; Middle Aged; Thiophenes | 2019 |
Long-term (52-week) efficacy and safety of ipragliflozin add-on therapy to insulin in Japanese patients with type 1 diabetes mellitus: An uncontrolled, open-label extension of a phase III study.
Topics: Aged; Asian People; Diabetes Mellitus, Type 1; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Humans; Insulin; Japan; Male; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Trans-Activators; Treatment Outcome | 2020 |
Beneficial Effects of Ipragliflozin on the Renal Function and Serum Uric Acid Levels in Japanese Patients with Type 2 Diabetes: A Randomized, 12-week, Open-label, Active-controlled Trial.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Drug Administration Schedule; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Japan; Male; Middle Aged; Renal Insufficiency, Chronic; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome; Uric Acid; Young Adult | 2020 |
Effects of ipragliflozin versus metformin in combination with sitagliptin on bone and muscle in Japanese patients with type 2 diabetes mellitus: Subanalysis of a prospective, randomized, controlled study (PRIME-V study).
Topics: Adult; Aged; Biomarkers; Blood Glucose; Bone and Bones; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studies; Glucosides; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Muscles; Prognosis; Prospective Studies; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Young Adult | 2021 |
Comparison of the Pharmacokinetic and Pharmacodynamic Relationship of Ipragliflozin Between Patients With Type 1 and Type 2 Diabetes Mellitus.
Topics: Adult; Aged; Area Under Curve; Blood Glucose; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2020 |
Mechanistic evaluation of the effect of sodium-dependent glucose transporter 2 inhibitors on delayed glucose absorption in patients with type 2 diabetes mellitus using a quantitative systems pharmacology model of human systemic glucose dynamics.
Topics: Adult; Benzhydryl Compounds; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Female; Glucose; Glucosides; Humans; Intestinal Absorption; Kidney; Male; Middle Aged; Models, Biological; Postprandial Period; Pyrazoles; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Thiazolidines; Thiophenes; Young Adult | 2020 |
A 52-week randomized controlled trial of ipragliflozin or sitagliptin in type 2 diabetes combined with metformin: The N-ISM study.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sitagliptin Phosphate; Thiophenes; Treatment Outcome | 2021 |
A randomized, placebo-controlled trial to assess the efficacy and safety of sitagliptin in Japanese patients with type 2 diabetes and inadequate glycaemic control on ipragliflozin.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Glycemic Control; Humans; Hypoglycemic Agents; Japan; Metformin; Middle Aged; Sitagliptin Phosphate; Thiophenes; Treatment Outcome | 2021 |
Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes and inadequate glycaemic control on sitagliptin.
Topics: Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Glycemic Control; Humans; Hypoglycemic Agents; Japan; Metformin; Middle Aged; Sitagliptin Phosphate; Thiophenes; Treatment Outcome | 2021 |
Ipragliflozin Improves the Hepatic Outcomes of Patients With Diabetes with NAFLD.
Topics: Aged; Body Mass Index; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Glycemic Control; Humans; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2022 |
The sodium-glucose cotransporter 2 inhibitor ipragliflozin improves liver function and insulin resistance in Japanese patients with type 2 diabetes.
Topics: Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucosides; Humans; Insulin; Insulin Resistance; Japan; Liver; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Time Factors; Treatment Outcome | 2022 |
Effects of ipragliflozin on left ventricular diastolic function in patients with type 2 diabetes and heart failure with preserved ejection fraction: The EXCEED randomized controlled multicenter study.
Topics: Aged; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Natriuretic Peptide, Brain; Stroke Volume; Thiophenes; Ventricular Function, Left | 2022 |
161 other study(ies) available for glucose, (beta-d)-isomer and thiophenes
| Article | Year |
|---|---|
Differential regulation of the activation of human eosinophils, macrophages, and neutrophils: effect of the allergic mediator release inhibitor CI-949.
Topics: Acetylglucosaminidase; Enzyme Inhibitors; Eosinophils; Humans; In Vitro Techniques; Lysosomes; Macrophage Activation; Macrophages; Neutrophils; Oxygen Consumption; Peroxidase; Superoxides; Tetrazoles; Thiophenes; Zymosan | 1990 |
Effect of ticlopidine on neutrophil chemotaxis in rats.
Topics: Adenosine Diphosphate; Administration, Oral; Animals; Cell Membrane; Chemotaxis, Leukocyte; Depression, Chemical; Male; Neutrophils; Platelet Aggregation; Rats; Thiophenes; Ticlopidine; Zymosan | 1985 |
Experience with 4'-demethylepipodo-phyllotoxin 9-(4,6-o-2-thenylidene-beta-D-glucopyranoside); VM-26; NSC-122819 in the treatment of malignant lymphosis.
Topics: Adult; Aged; Antineoplastic Agents; Blood Platelet Disorders; Dose-Response Relationship, Drug; Female; Glucosides; Glycosides; Hodgkin Disease; Humans; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Male; Middle Aged; Podophyllotoxin; Remission, Spontaneous; Thiophenes | 1974 |
Measurement and drug induced modulation of interleukin-1 level during zymosan peritonitis in mice.
Topics: Analysis of Variance; Animals; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Biological Assay; Dexamethasone; Disease Models, Animal; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Indomethacin; Interleukin-1; Male; Mice; Peritonitis; Thiophenes; Zymosan | 1995 |
Synthesis of a glucuronic acid and glucose conjugate library and evaluation of effects on endothelial cell growth.
Topics: Animals; Carbohydrate Conformation; Carbohydrate Sequence; Cattle; Cell Division; Cell Line; Combinatorial Chemistry Techniques; Endothelial Cells; Fibroblast Growth Factor 2; Glucose; Glucosides; Glucuronic Acid; Heparin; Mice; Molecular Sequence Data; Molecular Structure; Oligosaccharides; Serum Albumin; Structure-Activity Relationship; Thiophenes | 2004 |
Mechanisms involved in the anti-inflammatory action of inhaled tea tree oil in mice.
Topics: Administration, Inhalation; Animals; Anti-Inflammatory Agents; Cell Count; Cyclooxygenase Inhibitors; Hypothalamo-Hypophyseal System; Immunologic Factors; Leukocytes; Male; Mice; Mice, Inbred C57BL; Mice, Inbred CBA; Models, Biological; Peritoneal Cavity; Pituitary-Adrenal System; Prostaglandin-Endoperoxide Synthases; Pyrimidines; Pyrroles; Reactive Oxygen Species; Receptors, Corticotropin-Releasing Hormone; Tea Tree Oil; Tetradecanoylphorbol Acetate; Thiophenes; Zymosan | 2007 |
Increased cyclooxygenase activity impairs apoptosis of inflammatory neutrophils in mice lacking gelatinase B/matrix metalloproteinase-9.
Topics: Animals; Apoptosis; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Dinoprostone; Male; Matrix Metalloproteinase 9; Membrane Proteins; Mice; Mice, Knockout; Neutrophil Infiltration; Neutrophils; Peritonitis; Prostaglandin D2; Pyrazoles; Thiophenes; Zymosan | 2009 |
Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus.
Topics: Animals; Biological Availability; Canagliflozin; Carbonates; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Male; Mice; Rats; Rats, Sprague-Dawley; Sodium-Glucose Transporter 2 Inhibitors; Stereoisomerism; Structure-Activity Relationship; Thiophenes | 2010 |
New diabetes drugs go beyond insulin to flush out excess sugar.
Topics: Benzhydryl Compounds; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Thiophenes | 2011 |
Chemical constituents from Eupatorium chinense.
Topics: Eupatorium; Glucosides; Glycosides; Molecular Structure; Monoterpenes; Nuclear Magnetic Resonance, Biomolecular; Plant Roots; Thiophenes | 2011 |
Novel thiophenyl C-aryl glucoside SGLT2 inhibitors as potential antidiabetic agents.
Topics: Benzhydryl Compounds; Glucosides; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Structure-Activity Relationship; Thiophenes | 2011 |
Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo.
Topics: Animals; Blood Glucose; Carbohydrate Metabolism; CHO Cells; Cricetinae; Cricetulus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Gastrointestinal Tract; Glucosides; Humans; Hypoglycemic Agents; Insulin; Male; Mice; Mice, Inbred ICR; Phlorhizin; Rats; Rats, Sprague-Dawley; Sodium-Glucose Transporter 1; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2012 |
Drugs in traffic: the road to approval.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Abiraterone Acetate; Adenine; Androstadienes; Antibodies, Monoclonal, Humanized; Anticarcinogenic Agents; Benzhydryl Compounds; Bevacizumab; Drug Approval; Drug Industry; Glucosides; Hydroxyprogesterones; Indans; Morpholines; Natriuretic Peptide, Brain; Organophosphonates; Protein C; Recombinant Proteins; Rivaroxaban; Tenofovir; Thiophenes | 2011 |
Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models.
Topics: Animals; Blood Glucose; Body Weight; Canagliflozin; Cells, Cultured; CHO Cells; Cricetinae; Diabetes Mellitus, Experimental; Glucose Tolerance Test; Glucosides; Humans; Hyperglycemia; Kidney; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Muscle, Skeletal; Rats; Rats, Zucker; Sodium-Glucose Transport Proteins; Sodium-Glucose Transporter 1; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Weight Gain | 2012 |
Discovery of Ipragliflozin (ASP1941): a novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus.
Topics: Animals; Blood Glucose; CHO Cells; Cricetinae; Diabetes Mellitus, Type 2; Disease Models, Animal; Dose-Response Relationship, Drug; Glucosides; Humans; Hypoglycemic Agents; Inhibitory Concentration 50; Male; Mice; Molecular Structure; Rats; Rats, Sprague-Dawley; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2012 |
Antidiabetic effects of SGLT2-selective inhibitor ipragliflozin in streptozotocin-nicotinamide-induced mildly diabetic mice.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glucose; Glucose Tolerance Test; Glucosides; Hypoglycemic Agents; Insulin; Kidney; Male; Mice; Mice, Inbred ICR; Niacinamide; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Streptozocin; Thiophenes | 2012 |
Identification of Sensory-Active Phytochemicals in Asparagus (Asparagus officinalis L.).
Topics: Adult; Asparagus Plant; Chromatography, Liquid; Cooking; Female; Glucosides; Humans; Magnetic Resonance Spectroscopy; Male; Molecular Structure; Nontherapeutic Human Experimentation; Phytochemicals; Saponins; Sulfur Compounds; Tandem Mass Spectrometry; Taste; Thiophenes | 2012 |
Renal glucose handling: impact of chronic kidney disease and sodium-glucose cotransporter 2 inhibition in patients with type 2 diabetes.
Topics: Aged; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Female; Glomerular Filtration Rate; Glucose; Glucosides; Glycosuria; Humans; Male; Middle Aged; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2013 |
Canagliflozin approved for type 2 diabetes.
Topics: Canagliflozin; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Approval; Glucosides; Humans; Hypoglycemic Agents; Thiophenes; United States; United States Food and Drug Administration | 2013 |
Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Diet, High-Fat; Fatty Liver; Glucose Tolerance Test; Glucosides; Glycosuria; Hyperglycemia; Hyperlipidemias; Hypoglycemic Agents; Inflammation; Insulin; Insulin Resistance; Insulin Secretion; Male; Mice; Obesity; Oxidative Stress; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2013 |
Sodium glucose transporter 2 inhibition: a new approach to diabetes treatment.
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucosides; Glycosides; Humans; Hypoglycemia; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2013 |
The effect of moderate hepatic impairment on the pharmacokinetics of ipragliflozin, a novel sodium glucose co-transporter 2 (SGLT2) inhibitor.
Topics: Female; Glucosides; Humans; Liver; Male; Middle Aged; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2013 |
US approves "new class" of diabetes drug, under review in Canada.
Topics: Canada; Canagliflozin; Diabetes Mellitus, Type 2; Drug Approval; Glucosides; Humans; Hypoglycemic Agents; Thiophenes; United States | 2013 |
The top 10 drug trends right now.
Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Azepines; Biphenyl Compounds; Canagliflozin; Cholesterol Ester Transfer Proteins; Dimethyl Fumarate; Drug Approval; Forecasting; Fumarates; gamma-Cyclodextrins; Glucosides; Humans; Lactones; Maytansine; Pyridines; Sofosbuvir; Sugammadex; Thiophenes; Trastuzumab; Triazoles; United States; United States Food and Drug Administration; Uridine Monophosphate | 2013 |
A novel approach.
Topics: Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Glucosides; Humans; Kidney; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2013 |
C-Glucosides with heteroaryl thiophene as novel sodium-dependent glucose cotransporter 2 inhibitors.
Topics: Animals; Blood Glucose; Canagliflozin; Cell Line; CHO Cells; Cricetinae; Cricetulus; Diet, High-Fat; Glucosides; Half-Life; Humans; Hypoglycemic Agents; Male; Mice; Monosaccharides; Protein Binding; Pyridines; Rats; Rats, Sprague-Dawley; Sodium-Glucose Transporter 1; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2013 |
SGLT2 inhibitors for diabetes: turning symptoms into therapy.
Topics: Canagliflozin; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Thiophenes | 2013 |
Treating type 2 diabetes with canagliflozin.
Topics: Blood Pressure; Body Weight; Canagliflozin; Cholesterol, HDL; Diabetes Mellitus, Type 2; Glucosides; Humans; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome | 2013 |
Invokana (Canagliflozin) as a dual inhibitor of acetylcholinesterase and sodium glucose co-transporter 2: advancement in Alzheimer's disease- diabetes type 2 linkage via an enzoinformatics study.
Topics: Alzheimer Disease; Animals; Canagliflozin; Cholinesterase Inhibitors; Computer Simulation; Databases, Protein; Diabetes Mellitus, Type 2; Glucosides; Humans; Models, Molecular; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2014 |
Three-component cascade annulation of β-ketothioamides promoted by CF3CH2OH: a regioselective synthesis of tetrasubstituted thiophenes.
Topics: Glucosides; Molecular Structure; Stereoisomerism; Thioamides; Thiophenes | 2013 |
Synthesis and biological evaluation of thiophene-C-glucosides as sodium-dependent glucose cotransporter 2 inhibitors.
Topics: Animals; Body Weight; CHO Cells; Cricetinae; Cricetulus; Glucose; Glucosides; Humans; Hypoglycemic Agents; Male; Rats; Rats, Sprague-Dawley; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Sorbitol; Structure-Activity Relationship; Thiophenes | 2013 |
Canagliflozin versus glimepiride treatment in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU trial).
Topics: Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Thiophenes | 2014 |
Canagliflozin - something new for type 2 diabetes, but is it safe and efficacious?
Topics: Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Thiophenes | 2014 |
Effect of SGLT2 inhibitors in a murine model of urinary tract infection with Candida albicans.
Topics: Animals; Benzhydryl Compounds; Canagliflozin; Candida albicans; Candidiasis; Disease Progression; Female; Glucosides; Glycosuria; Kidney; Mice; Mice, Inbred C57BL; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Urinary Tract Infections | 2014 |
[Introduction].
Topics: Benzhydryl Compounds; Biological Transport, Active; Canagliflozin; Diabetes Mellitus, Type 2; Glucose; Glucosides; Humans; Hypoglycemic Agents; Kidney Tubules, Proximal; Sodium-Glucose Transporter 1; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2013 |
Safety of canagliflozin in patients with type 2 diabetes.
Topics: Canagliflozin; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hyperkalemia; Hypoglycemic Agents; Lipids; Male; Thiophenes; Urinary Tract Infections; Urination | 2014 |
SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats.
Topics: Adiposity; Animals; Anti-Obesity Agents; Biomarkers; Blood Glucose; Diet, High-Fat; Disease Models, Animal; Energy Metabolism; Fatty Acids; Glucosides; Glycosuria; Hypoglycemic Agents; Lipid Metabolism; Obesity; Oxidation-Reduction; Rats; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Time Factors; Up-Regulation; Weight Loss | 2014 |
Canagliflozin.
Topics: Diabetes Mellitus, Type 2; Glucosides; Humans; Thiophenes | 2014 |
Canagliflozin.
Topics: Diabetes Mellitus, Type 2; Glucosides; Humans; Thiophenes | 2014 |
In reply.
Topics: Diabetes Mellitus, Type 2; Glucosides; Humans; Thiophenes | 2014 |
Effects of sodium-glucose cotransporter 2 selective inhibitor ipragliflozin on hyperglycaemia, oxidative stress, inflammation and liver injury in streptozotocin-induced type 1 diabetic rats.
Topics: Albuminuria; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Fatty Liver; Glomerular Filtration Rate; Glucose Intolerance; Glucosides; Hyperglycemia; Hyperlipidemias; Hypoglycemic Agents; Inflammation; Kidney; Liver; Male; Oxidative Stress; Rats, Sprague-Dawley; Sodium-Glucose Transporter 2 Inhibitors; Streptozocin; Thiophenes | 2014 |
Ipragliflozin: first global approval.
Topics: Animals; Diabetes Mellitus, Type 2; Drug Approval; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemic Agents; Japan; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2014 |
Glucotoxicity targets hepatic glucokinase in Zucker diabetic fatty rats, a model of type 2 diabetes associated with obesity.
Topics: Animals; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Eating; Glucagon; Glucokinase; Glucose; Glucose Clamp Technique; Glucosides; Hyperglycemia; Hyperinsulinism; Immunohistochemistry; Liver; Male; Obesity; Organ Size; Oxygen Consumption; Rats; Rats, Zucker; RNA, Messenger; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2014 |
Efficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: a pooled analysis of clinical studies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Canagliflozin; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Male; Meta-Analysis as Topic; Middle Aged; Prognosis; Randomized Controlled Trials as Topic; Thiophenes; Young Adult | 2014 |
The Author's Reply:.
Topics: Animals; Benzhydryl Compounds; Glomerular Filtration Rate; Glucose; Glucosides; Humans; Hypoglycemic Agents; Renal Insufficiency, Chronic; Thiophenes | 2014 |
A nephrologist's point of view on sodium-glucose linked transporter-2 inhibitors: not all that glitters is gold.
Topics: Animals; Benzhydryl Compounds; Glomerular Filtration Rate; Glucose; Glucosides; Humans; Hypoglycemic Agents; Renal Insufficiency, Chronic; Thiophenes | 2014 |
Safety and tolerability of canagliflozin in patients with type 2 diabetes mellitus: pooled analysis of phase 3 study results.
Topics: Canagliflozin; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Incidence; Kidney Function Tests; Lipids; Male; Middle Aged; Randomized Controlled Trials as Topic; Severity of Illness Index; Sex Factors; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2014 |
Efficacy and safety of canagliflozin in patients with type 2 diabetes and stage 3 nephropathy.
Topics: Aged; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Glomerular Filtration Rate; Glucosides; Glycated Hemoglobin; Humans; Hypertension; Hypoglycemic Agents; Male; Middle Aged; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Severity of Illness Index; Thiophenes; Treatment Outcome | 2014 |
Carbohydrate malabsorption mechanism for tumor formation in rats treated with the SGLT2 inhibitor canagliflozin.
Topics: Animals; Canagliflozin; Carbohydrate Metabolism, Inborn Errors; Carcinogenesis; Cell Adhesion Molecules; Cell Proliferation; Glucosides; Immunohistochemistry; Kidney; Malabsorption Syndromes; Male; Rats; Rats, Sprague-Dawley; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2014 |
Analysis of the effect of canagliflozin on renal glucose reabsorption and progression of hyperglycemia in zucker diabetic Fatty rats.
Topics: Animals; Blood Glucose; Canagliflozin; Diabetes Mellitus, Experimental; Dogs; Glucose; Glucosides; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Islets of Langerhans; Kidney; Mice; Rats; Rats, Zucker; Sodium-Glucose Transporter 2; Thiophenes | 2014 |
How a β-D-glucoside side chain enhances binding affinity to thrombin of inhibitors bearing 2-chlorothiophene as P1 moiety: crystallography, fragment deconstruction study, and evaluation of antithrombotic properties.
Topics: Anticoagulants; Antithrombins; Binding Sites; Chemistry Techniques, Synthetic; Crystallography, X-Ray; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Fibrin; Fibrinolysis; Glucosides; Humans; Hydrogen Bonding; Models, Molecular; Structure-Activity Relationship; Thiophenes; Thrombin | 2014 |
Carcinogenicity in rats of the SGLT2 inhibitor canagliflozin.
Topics: Adrenal Gland Neoplasms; Animals; Canagliflozin; Carcinogenesis; Carcinogenicity Tests; Dose-Response Relationship, Drug; Glucosides; Kidney Neoplasms; Kidney Tubules; Leydig Cell Tumor; Male; Pheochromocytoma; Rats; Rats, Sprague-Dawley; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Structure-Activity Relationship; Testicular Neoplasms; Thiophenes | 2014 |
Antihyperglycemic effect of ipragliflozin, a sodium-glucose co-transporter 2 inhibitor, in combination with oral antidiabetic drugs in mice.
Topics: Administration, Oral; Animals; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucosides; Hypoglycemic Agents; Male; Mice; Mice, Inbred ICR; Mice, Transgenic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome | 2015 |
Ameliorated pancreatic β cell dysfunction in type 2 diabetic patients treated with a sodium-glucose cotransporter 2 inhibitor ipragliflozin.
Topics: Adult; Algorithms; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glucose Tolerance Test; Glucosides; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Insulin-Secreting Cells; Japan; Male; Middle Aged; Pilot Projects; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2015 |
Effect of canagliflozin on blood pressure and adverse events related to osmotic diuresis and reduced intravascular volume in patients with type 2 diabetes mellitus.
Topics: Aged; Blood Pressure; Blood Pressure Determination; Canagliflozin; Diabetes Mellitus, Type 2; Diuresis; Female; Glucosides; Humans; Hypertension; Male; Middle Aged; Sodium-Glucose Transporter 2; Thiophenes | 2014 |
Characteristics and short-term outcomes of patients with type 2 diabetes mellitus treated with canagliflozin in a real-world setting.
Topics: Adult; Aged; Blood Glucose; Canagliflozin; Databases, Factual; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Medicare Part C; Middle Aged; Retrospective Studies; Thiophenes; Treatment Outcome; United States | 2015 |
Sodium glucose cotransport-2 inhibition and intrarenal RAS activity in people with type 1 diabetes.
Topics: Animals; Benzhydryl Compounds; Glomerular Filtration Rate; Glucose; Glucosides; Humans; Hypoglycemic Agents; Renal Insufficiency, Chronic; Thiophenes | 2014 |
The author replies.
Topics: Animals; Benzhydryl Compounds; Glomerular Filtration Rate; Glucose; Glucosides; Humans; Hypoglycemic Agents; Renal Insufficiency, Chronic; Thiophenes | 2014 |
The authors reply.
Topics: Animals; Benzhydryl Compounds; Glomerular Filtration Rate; Glucose; Glucosides; Humans; Hypoglycemic Agents; Renal Insufficiency, Chronic; Thiophenes | 2014 |
Evaluation of pharmacokinetic and pharmacodynamic interactions of canagliflozin and teneligliptin in Japanese healthy male volunteers.
Topics: Adult; Asian People; Canagliflozin; Cross-Over Studies; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Drug Evaluation; Drug Interactions; Glucosides; Healthy Volunteers; Humans; Male; Pyrazoles; Thiazolidines; Thiophenes; Young Adult | 2015 |
Increased urine output by ipragliflozin in a non-diabetic patient with a diuretic-resistant heart failure.
Topics: Diabetes Mellitus; Diuresis; Diuretics; Dose-Response Relationship, Drug; Drug Resistance; Female; Glucosides; Heart Failure; Humans; Middle Aged; Stroke Volume; Thiophenes | 2015 |
Rapid determination of canagliflozin in rat plasma by UHPLC-MS/MS using negative ionization mode to avoid adduct-ions formation.
Topics: Acetonitriles; Administration, Oral; Animals; Canagliflozin; Chromatography, High Pressure Liquid; Drug Stability; Glucosides; Hypoglycemic Agents; Indoles; Limit of Detection; Male; Phenylcarbamates; Rats; Rats, Wistar; Reference Standards; Reproducibility of Results; Spectrometry, Mass, Electrospray Ionization; Sulfonamides; Tandem Mass Spectrometry; Thiophenes; Time Factors; Tosyl Compounds; Water | 2015 |
Glycosuria medicated with ipragliflozin and nifedipine or ipragliflozin and candesartan: a case report.
Topics: Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Calcium Channel Blockers; Drug Therapy, Combination; Glucosides; Glycosuria; Humans; Male; Middle Aged; Nifedipine; Tetrazoles; Thiophenes; Treatment Outcome | 2014 |
What is the place of new SGLT-2 inhibitors in therapy and on the formulary?
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Formularies as Topic; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2014 |
Ipragliflozin, an SGLT2 inhibitor, exhibits a prophylactic effect on hepatic steatosis and fibrosis induced by choline-deficient l-amino acid-defined diet in rats.
Topics: Amino Acids; Animals; Choline Deficiency; Food, Formulated; Glucosides; Hydroxyproline; Hypoglycemic Agents; Inflammation; Liver Cirrhosis; Male; Non-alcoholic Fatty Liver Disease; Pioglitazone; Rats; Sodium-Glucose Transporter 2 Inhibitors; Thiazolidinediones; Thiophenes; Triglycerides | 2015 |
Blood pressure reduction: an added benefit of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes.
Topics: Benzhydryl Compounds; Blood Pressure; Canagliflozin; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glucosides; Humans; Hypertension; Hypoglycemic Agents; Middle Aged; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2015 |
Canagliflozin (Invokana). A "me-too" of the dangerous dapagliflozin.
Topics: Benzhydryl Compounds; Biomarkers; Canagliflozin; Diabetes Complications; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Risk Assessment; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome | 2015 |
Sodium glucose transporter 2 (sglt2) inhibitors: Current status in clinical practice.
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2014 |
Response to the letter by Akinori Sairaku et al.: Different mechanisms = synergic effect.
Topics: Diuresis; Drug Resistance; Female; Glucosides; Heart Failure; Humans; Stroke Volume; Thiophenes | 2015 |
A quantitative LC-MS/MS method for determining ipragliflozin, a sodium-glucose co-transporter 2 (SGLT-2) inhibitor, and its application to a pharmacokinetic study in rats.
Topics: Animals; Chromatography, Liquid; Drug Stability; Glucosides; Limit of Detection; Linear Models; Male; Rats; Rats, Wistar; Reproducibility of Results; Sodium-Glucose Transporter 2 Inhibitors; Tandem Mass Spectrometry; Thiophenes | 2015 |
Diuretic effects of sodium-glucose cotransporter 2 inhibitor in patients with type 2 diabetes mellitus and heart failure.
Topics: Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Diuretics; Female; Glucosides; Heart Failure; Humans; Male; Middle Aged; Prospective Studies; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2015 |
Effects of the combination of SGLT2 selective inhibitor ipragliflozin and various antidiabetic drugs in type 2 diabetic mice.
Topics: Animals; Biomarkers; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, High-Fat; Dose-Response Relationship, Drug; Drug Therapy, Combination; Glucosides; Hypoglycemic Agents; Kidney; Male; Mice, Inbred ICR; Niacinamide; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Streptozocin; Thiophenes; Time Factors | 2016 |
Saponarin activates AMPK in a calcium-dependent manner and suppresses gluconeogenesis and increases glucose uptake via phosphorylation of CRTC2 and HDAC5.
Topics: AMP-Activated Protein Kinases; Apigenin; Benzimidazoles; Biphenyl Compounds; Calcium; Calcium-Calmodulin-Dependent Protein Kinase Kinase; Cyclic AMP Response Element-Binding Protein; Enzyme Activators; Forkhead Box Protein O1; Forkhead Transcription Factors; Gluconeogenesis; Glucose; Glucose Transporter Type 4; Glucosides; Hep G2 Cells; Histone Deacetylases; Humans; Insulin Resistance; Metformin; Naphthalimides; Phosphorylation; Pyrones; Thiophenes; Transcription Factors | 2015 |
SGLT2 inhibitors provide an effective therapeutic option for diabetes complicated with insulin antibodies.
Topics: Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Insulin Antibodies; Male; Middle Aged; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome | 2016 |
The Selective SGLT2 Inhibitor Ipragliflozin Has a Therapeutic Effect on Nonalcoholic Steatohepatitis in Mice.
Topics: Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Glucosides; Hypoglycemic Agents; Insulin Resistance; Mice; Non-alcoholic Fatty Liver Disease; Obesity; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome | 2016 |
Safety of ipragliflozin in elderly Japanese patients with type 2 diabetes mellitus (STELLA-ELDER): Interim results of a post-marketing surveillance study.
Topics: Aged; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Incidence; Product Surveillance, Postmarketing; Surveys and Questionnaires; Thiophenes | 2016 |
Effect of ipragliflozin, an SGLT2 inhibitor, on progression of diabetic microvascular complications in spontaneously diabetic Torii fatty rats.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Diabetic Neuropathies; Diabetic Retinopathy; Disease Progression; Glucosides; Hyperglycemia; Hypoglycemic Agents; Male; Rats; Rats, Sprague-Dawley; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2016 |
Effectiveness of Ipragliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor, as a Second-line Treatment for Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Who Do Not Respond to Incretin-Based Therapies Including Glucagon-like Pep
Topics: Alanine Transaminase; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glucagon-Like Peptide 1; Glucosides; Humans; Incretins; Liver Cirrhosis; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Retrospective Studies; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Weight Loss | 2016 |
Characterization and comparison of sodium-glucose cotransporter 2 inhibitors in pharmacokinetics, pharmacodynamics, and pharmacologic effects.
Topics: Animals; Benzhydryl Compounds; Blood Glucose; Canagliflozin; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Glucosides; Glycosuria; Hypoglycemic Agents; Male; Mice, Inbred ICR; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Sorbitol; Thiophenes; Tissue Distribution | 2016 |
Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction.
Topics: Adipose Tissue; Adult; Animals; Body Weight; Diabetes Mellitus, Type 2; Diet, High-Fat; Drug Evaluation, Preclinical; Energy Intake; Epididymis; Glucose; Glucosides; Humans; Hyperphagia; Hypoglycemic Agents; Insulin Resistance; Leptin; Lipids; Liver; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Non-alcoholic Fatty Liver Disease; Obesity; Organ Size; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Weight Loss | 2016 |
Ipragliflozin, a sodium-glucose cotransporter 2 inhibitor, ameliorates the development of liver fibrosis in diabetic Otsuka Long-Evans Tokushima fatty rats.
Topics: Animals; Body Weight; Cell Proliferation; Cells, Cultured; Diabetes Mellitus, Experimental; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Glucosides; Hepatic Stellate Cells; Hypoglycemic Agents; Insulin Resistance; Liver; Liver Cirrhosis, Experimental; Male; Obesity; Organ Size; Rats, Inbred OLETF; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2016 |
Ipragliflozin effectively reduced visceral fat in Japanese patients with type 2 diabetes under adequate diet therapy.
Topics: Adult; Aged; Body Composition; Body Mass Index; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Intra-Abdominal Fat; Japan; Male; Middle Aged; Obesity; Thiophenes; Young Adult | 2016 |
Renal threshold for glucose reabsorption predicts diabetes improvement by sodium-glucose cotransporter 2 inhibitor therapy.
Topics: Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Glycosuria; Humans; Hypoglycemic Agents; Male; Middle Aged; Renal Reabsorption; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome | 2016 |
[Efficacy of Ipragliflozin in Patients with Steroid-Induced Hyperglycemia during Cancer Chemotherapy].
Topics: Antiemetics; Blood Glucose; Chemoradiotherapy; Dexamethasone; Esophageal Neoplasms; Glucosides; Humans; Hyperglycemia; Male; Middle Aged; Neoplasm Staging; Thiophenes | 2016 |
Sodium-Glucose Cotransporter 2 Inhibitor and a Low Carbohydrate Diet Affect Gluconeogenesis and Glycogen Content Differently in the Kidney and the Liver of Non-Diabetic Mice.
Topics: Animals; Body Weight; Cyclic AMP Response Element-Binding Protein; Diabetes Mellitus, Experimental; Diet, Carbohydrate-Restricted; Energy Intake; Fatty Acid Synthases; Forkhead Box Protein O1; Gluconeogenesis; Glucose Tolerance Test; Glucosides; Glycogen; Hyperglycemia; Insulin Resistance; Kidney; Lipid Metabolism; Liver; Male; Mice, Inbred C57BL; Obesity; RNA, Messenger; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Triglycerides; Up-Regulation | 2016 |
Fluctuation in Serum Sodium Levels Related to Ipragliflozin Administration in a Patient with Diabetic Nephropathy and Sequela of Traumatic Brain Injury.
Topics: Brain Injuries, Traumatic; Diabetes Mellitus; Diabetic Nephropathies; Fludrocortisone; Glucosides; Humans; Hyponatremia; Insulin; Male; Middle Aged; Sodium; Thiophenes | 2016 |
Baseline characteristics and interim (3-month) efficacy and safety data from STELLA-LONG TERM, a long-term post-marketing surveillance study of ipragliflozin in Japanese patients with type 2 diabetes in real-world clinical practice.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incidence; Male; Middle Aged; Product Surveillance, Postmarketing; Prospective Studies; Thiophenes; Young Adult | 2016 |
Real-world evidence for the safety of ipragliflozin in elderly Japanese patients with type 2 diabetes mellitus (STELLA-ELDER): final results of a post-marketing surveillance study.
Topics: Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Product Surveillance, Postmarketing; Risk Factors; Surveys and Questionnaires; Thiophenes | 2016 |
A post-hoc analysis of the comparative efficacy of canagliflozin and glimepiride in the attainment of type 2 diabetes-related quality measures.
Topics: Aged; Blood Glucose; Blood Pressure Determination; Canagliflozin; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Quality Indicators, Health Care; Randomized Controlled Trials as Topic; Sulfonylurea Compounds; Thiophenes; Treatment Outcome | 2016 |
Predictors of response to ipragliflozin treatment in patients with type 2 diabetes mellitus.
Topics: Aged; Alanine Transaminase; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Humans; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2016 |
Distinct Glucose-Lowering Mechanisms of Ipragliflozin Depending on Body Weight Changes.
Topics: Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Glucosides; Homeostasis; Humans; Insulin Resistance; Insulin-Secreting Cells; Male; Middle Aged; Thiophenes | 2016 |
Visualization of mechanism of action, and a further therapeutic potential of ipragliflozin, a selective SGLT2 inhibitor.
Topics: Adipose Tissue; Animals; Body Weight; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2016 |
Cilostazol Suppresses IL-23 Production in Human Dendritic Cells via an AMPK-Dependent Pathway.
Topics: AMP-Activated Protein Kinases; Biphenyl Compounds; Cell Count; Cell Survival; Cilostazol; Dendritic Cells; HEK293 Cells; Humans; Interleukin-23; Monocytes; Myeloid Differentiation Factor 88; Phosphorylation; Promoter Regions, Genetic; Protein Subunits; Pyrones; Signal Transduction; Tetrazoles; Thiophenes; Transcription, Genetic; Zymosan | 2016 |
Amelioration of fatty liver index in patients with type 2 diabetes on ipragliflozin: an association with glucose-lowering effects.
Topics: Adiposity; Adult; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Japan; Lipotropic Agents; Liver; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Prospective Studies; Severity of Illness Index; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2017 |
Canagliflozin as an Initial Therapy in Drug-Naïve Subjects with Type 2 Diabetes Mellitus: A Potential Involvement of Atherogenic Lipids in its Glycemic Efficacy.
Topics: Atherosclerosis; Blood Glucose; Body Mass Index; Canagliflozin; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipids; Male; Middle Aged; Thiophenes; Triglycerides | 2017 |
Sodium-Glucose Cotransporter 2 Inhibitor Improves Complications of Lipodystrophy: A Case Report.
Topics: Adult; Diabetes Mellitus; Fatty Liver; Glucosides; Glycated Hemoglobin; Humans; Insulin Resistance; Lipodystrophy; Male; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2017 |
Mechanism of the blood pressure-lowering effect of sodium-glucose cotransporter 2 inhibitors in obese patients with type 2 diabetes.
Topics: Adult; Antihypertensive Agents; Benzhydryl Compounds; Blood Pressure; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypertension; Male; Middle Aged; Obesity; Plasma Volume; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2017 |
The Sodium Glucose Cotransporter 2 Inhibitor Ipragliflozin Promotes Preferential Loss of Fat Mass in Non-obese Diabetic Goto-Kakizaki Rats.
Topics: Absorptiometry, Photon; Adipose Tissue; Animals; Body Composition; Diabetes Mellitus, Type 2; Diet, High-Fat; Eating; Glucosides; Glycosuria; Hypoglycemic Agents; Male; Rats; Rats, Wistar; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Weight Loss | 2017 |
Anti-inflammatory and anti-nociceptive effects of strontium ranelate on the zymosan-induced temporomandibular joint inflammatory hypernociception in rats depend on TNF-α inhibition.
Topics: Animals; Drug Interactions; Enzyme-Linked Immunosorbent Assay; Inflammation; Interleukin-1beta; Male; Pain; Protoporphyrins; Rats; Rats, Wistar; Temporomandibular Joint Disorders; Thiophenes; Tumor Necrosis Factor-alpha; Zymosan | 2017 |
Atypical Ketoacidosis and Protracted Hyperglycosuria after Treatment with Ipragliflozin, an SGLT2 Inhibitor.
Topics: Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Ketosis; Obesity; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Young Adult | 2017 |
Insulin stimulates uric acid reabsorption via regulating urate transporter 1 and ATP-binding cassette subfamily G member 2.
Topics: Animals; Anion Transport Proteins; ATP Binding Cassette Transporter, Subfamily G, Member 2; Blood Glucose; Cell Line; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Glucosides; Hypoglycemic Agents; Insulin; Kidney Tubules; Male; Rats, Sprague-Dawley; Renal Elimination; Renal Reabsorption; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Streptozocin; Thiophenes; Time Factors; Uric Acid | 2017 |
Ipragliflozin, a sodium glucose co-transporter 2 inhibitor, reduces intrahepatic lipid content and abdominal visceral fat volume in patients with type 2 diabetes.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Glucosides; Humans; Intra-Abdominal Fat; Lipids; Liver; Magnetic Resonance Spectroscopy; Male; Obesity; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Tomography, X-Ray Computed | 2017 |
The Improvement of the Hepatic Histological Findings in a Patient with Non-alcoholic Steatohepatitis with Type 2 Diabetes after the Administration of the Sodium-glucose Cotransporter 2 Inhibitor Ipragliflozin.
Topics: Aged; Alanine Transaminase; Diabetes Mellitus, Type 2; Female; Ferritins; Glucosides; Humans; Hypoglycemic Agents; Liver Function Tests; Non-alcoholic Fatty Liver Disease; Sodium-Glucose Transporter 2; Thiophenes | 2017 |
Time-dependent effects of ipragliflozin on behaviour and energy homeostasis in normal and type 2 diabetic rats: continuous glucose telemetry analysis.
Topics: Animals; Blood Glucose; Body Temperature; Circadian Rhythm; Diabetes Mellitus, Type 2; Drinking; Eating; Energy Metabolism; Glucosides; Glycosuria; Hypoglycemic Agents; Male; Rats; Rats, Wistar; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2017 |
Switching from low-dose thiazide diuretics to sodium-glucose cotransporter 2 inhibitor improves various metabolic parameters without affecting blood pressure in patients with type 2 diabetes and hypertension.
Topics: Aged; Blood Pressure; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypertension; Hypoglycemic Agents; Male; Middle Aged; Sodium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome | 2018 |
Antidiabetic and antiobesity effects of SGLT2 inhibitor ipragliflozin in type 2 diabetic mice fed sugar solution.
Topics: Adipose Tissue; Animal Feed; Animals; Body Weight; Diabetes Mellitus, Type 2; Glucosides; Hypoglycemic Agents; Male; Mice; Mice, Inbred ICR; Obesity; Sodium-Glucose Transporter 2 Inhibitors; Solutions; Sugars; Thiophenes | 2018 |
Safety and efficacy of ipragliflozin in Japanese patients with type 2 diabetes in real-world clinical practice: interim results of the STELLA-LONG TERM post-marketing surveillance study.
Topics: Adult; Aged; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Heart Rate; Humans; Hypoglycemic Agents; Japan; Kidney Diseases; Lipoproteins, LDL; Male; Middle Aged; Product Surveillance, Postmarketing; Registries; Thiophenes; Treatment Outcome; Triglycerides | 2018 |
Alkyl polyglucoside vs. ethoxylated surfactant-based microemulsions as vehicles for two poorly water-soluble drugs: physicochemical characterization and in vivo skin performance.
Topics: Adapalene; Administration, Cutaneous; Adult; Caprylates; Emulsions; Glucosides; Humans; Imidazoles; Microscopy, Polarization; Pharmaceutical Vehicles; Polysorbates; Skin; Skin Irritancy Tests; Solubility; Spectroscopy, Fourier Transform Infrared; Surface-Active Agents; Thiophenes | 2017 |
Ipragliflozin improves mitochondrial abnormalities in renal tubules induced by a high-fat diet.
Topics: Animals; Diet, High-Fat; Energy Intake; Glucosides; Kidney Diseases; Kidney Tubules; Male; Mice; Mice, Inbred C57BL; Mitochondria; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2018 |
Effects of the SGLT2 inhibitor ipragliflozin on various diabetic symptoms and progression of overt nephropathy in type 2 diabetic mice.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Glucose; Glucosides; Hypoglycemic Agents; Kidney; Male; Mice, Inbred ICR; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2018 |
Safety and efficacy of ipragliflozin in elderly versus non-elderly Japanese patients with type 2 diabetes mellitus: a subgroup analysis of the STELLA-LONG TERM study.
Topics: Aged; Asian People; Blood Glucose; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incidence; Japan; Kidney Diseases; Lipoproteins, LDL; Male; Middle Aged; Product Surveillance, Postmarketing; Prospective Studies; Skin Diseases; Thiophenes; Treatment Outcome | 2018 |
Antidiabetic effects of SGLT2 inhibitor ipragliflozin in type 2 diabetic mice fed diets containing different carbohydrate contents.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet; Dietary Carbohydrates; Glucosides; Hypoglycemic Agents; Mice; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2018 |
Long-term use of ipragliflozin improved cardiac sympathetic nerve activity in a patient with heart failure: A case report.
Topics: Aged, 80 and over; Body Weight; Glucosides; Heart Failure; Hospitalization; Humans; Male; Myocardial Perfusion Imaging; Sympathetic Nervous System; Thiophenes; Treatment Outcome | 2018 |
Comprehensive renoprotective effects of ipragliflozin on early diabetic nephropathy in mice.
Topics: Animals; Glucosides; Kidney; Male; Mice; Mice, Inbred BALB C; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2018 |
Prevention of progression of diabetic nephropathy by the SGLT2 inhibitor ipragliflozin in uninephrectomized type 2 diabetic mice.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glucosides; Hypertension; Kidney; Losartan; Male; Mice, Inbred C57BL; Nephrectomy; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2018 |
Protective Effect of Ipragliflozin on Pancreatic Islet Cells in Obese Type 2 Diabetic db/db Mice.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Fatty Acids; Glucosides; Glycated Hemoglobin; Hypoglycemic Agents; Insulin; Islets of Langerhans; Lipid Metabolism; Male; Mice; Mice, Obese; Obesity; Oxidative Stress; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Triglycerides | 2018 |
Unmasking a sustained negative effect of SGLT2 inhibition on body fluid volume in the rat.
Topics: Animals; Body Composition; Diabetes Mellitus, Type 2; Disease Models, Animal; Diuresis; Drinking; Eating; Epithelial Sodium Channels; Glucosides; Male; Natriuresis; Rats, Sprague-Dawley; Sodium; Sodium-Glucose Transporter 1; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Sodium-Hydrogen Exchanger 3; Thiophenes; Time Factors; Water-Electrolyte Balance | 2018 |
Susceptibility to serious skin and subcutaneous tissue disorders and skin tissue distribution of sodium-dependent glucose co-transporter type 2 (SGLT2) inhibitors.
Topics: Animals; Glucose; Glucose Transporter Type 2; Glucosides; Humans; Hypoglycemic Agents; Japan; Rats; Skin Diseases; Sodium; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Subcutaneous Tissue; Thiophenes; Tissue Distribution | 2018 |
Effects of the SGLT2 inhibitor ipragliflozin on food intake, appetite-regulating hormones, and arteriovenous differences in postprandial glucose levels in type 2 diabetic rats.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Eating; Ghrelin; Glucosides; Hypoglycemic Agents; Male; Postprandial Period; Rats; Rats, Wistar; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome | 2018 |
Sodium-glucose cotransporter 2 inhibition normalizes glucose metabolism and suppresses oxidative stress in the kidneys of diabetic mice.
Topics: Animals; Blood Glucose; Caloric Restriction; Citric Acid Cycle; Diabetes Mellitus, Experimental; Glucose; Glucosides; Kidney; Male; Mice; Mice, Obese; Oxidative Stress; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2018 |
Should sulfonylurea be discontinued or maintained at the lowest dose when starting ipragliflozin? A multicenter observational study in Japanese patients with type 2 diabetes.
Topics: Biomarkers; Blood Glucose; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studies; Glucosides; Glycated Hemoglobin; Humans; Japan; Male; Middle Aged; Prognosis; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Thiophenes | 2019 |
A reduced M1-like/M2-like ratio of macrophages in healthy adipose tissue expansion during SGLT2 inhibition.
Topics: 3T3-L1 Cells; Adipose Tissue; Animals; Anisoles; Cell Polarity; Ceramides; Diet, High-Fat; Down-Regulation; Glucosides; Interleukin-15; Intracellular Signaling Peptides and Proteins; Ketone Bodies; Lipids; Macrophages; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Phenotype; Phosphoenolpyruvate Carboxykinase (GTP); Pyrimidines; Receptor, Macrophage Colony-Stimulating Factor; Receptors, CCR2; Signal Transduction; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Sphingomyelins; Thiophenes; Up-Regulation | 2018 |
Effect of ipragliflozin on liver function in Japanese type 2 diabetes mellitus patients: a subgroup analysis of the STELLA-LONG TERM study (3-month interim results).
Topics: Aged; Alanine Transaminase; Alkaline Phosphatase; Asian People; Aspartate Aminotransferases; Diabetes Mellitus, Type 2; Female; gamma-Glutamyltransferase; Glucosides; Humans; Japan; Liver; Liver Function Tests; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Product Surveillance, Postmarketing; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2019 |
First-dose effect of the SGLT2 inhibitor ipragliflozin on cardiovascular activity in spontaneously diabetic Torii fatty rats.
Topics: Animals; Autonomic Nervous System; Blood Pressure; Cardiovascular System; Diabetes Mellitus, Experimental; Dose-Response Relationship, Drug; Glucosides; Heart Rate; Rats; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Urinalysis | 2019 |
Effects of ipragliflozin on glycemic control, appetite and its related hormones: A prospective, multicenter, open-label study (SOAR-KOBE Study).
Topics: Appetite; Biomarkers; Blood Glucose; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Eating; Female; Follow-Up Studies; Ghrelin; Glucosides; Glycated Hemoglobin; Glycemic Index; Humans; Leptin; Male; Middle Aged; Prognosis; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Weight Loss | 2019 |
Safety and efficacy of tofogliflozin in Japanese patients with type 2 diabetes mellitus in real-world clinical practice: Results of 3-month interim analysis of a long-term post-marketing surveillance study (J-STEP/LT).
Topics: Adolescent; Adult; Aged; Biomarkers; Blood Glucose; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glucosides; Glycated Hemoglobin; Humans; Japan; Male; Middle Aged; Practice Patterns, Physicians'; Product Surveillance, Postmarketing; Prognosis; Prospective Studies; Safety; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Young Adult | 2019 |
Impact of body mass index on the efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes mellitus: A subgroup analysis of 3-month interim results from the Specified Drug Use Results Survey of Ipragliflozin Treatment in Type 2 Diabet
Topics: Biomarkers; Blood Glucose; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glucosides; Glycated Hemoglobin; Humans; Japan; Male; Middle Aged; Product Surveillance, Postmarketing; Prognosis; Safety; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Weight Loss | 2019 |
Safety and Effectiveness of Ipragliflozin for Type 2 Diabetes in Japan: 12-Month Interim Results of the STELLA-LONG TERM Post-Marketing Surveillance Study.
Topics: Body Weight; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Japan; Liver Function Tests; Longitudinal Studies; Male; Middle Aged; Pharmacovigilance; Product Surveillance, Postmarketing; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2019 |
In Vitro Pharmacological Profile of Ipragliflozin, a Sodium Glucose Co-transporter 2 Inhibitor.
Topics: Animals; CHO Cells; Cricetinae; Cricetulus; Dose-Response Relationship, Drug; Glucosides; Humans; Molecular Structure; Phlorhizin; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2019 |
Ipragliflozin-induced adipose expansion inhibits cuff-induced vascular remodeling in mice.
Topics: Adipocytes; Adipogenesis; Adipose Tissue; Adiposity; Animals; Cells, Cultured; Diabetes Mellitus, Type 2; Diet, High-Fat; Disease Models, Animal; Fibrosis; Glucosides; Inflammation Mediators; Insulin Resistance; Macrophages; Male; Mice, Inbred C57BL; Mice, Knockout, ApoE; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Obesity; Paracrine Communication; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Vascular Remodeling; Vascular System Injuries | 2019 |
A Lower Baseline Urinary Glucose Excretion Predicts a Better Response to the Sodium Glucose Cotransporter 2 Inhibitor.
Topics: Adult; Aged; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glucosides; Glycated Hemoglobin; Glycosuria; Humans; Hypoglycemic Agents; Male; Middle Aged; Prospective Studies; Republic of Korea; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome; Young Adult | 2019 |
Cardiac ischemia-reperfusion injury under insulin-resistant conditions: SGLT1 but not SGLT2 plays a compensatory protective role in diet-induced obesity.
Topics: Animals; Benzhydryl Compounds; Blood Glucose; Canagliflozin; Diet, High-Fat; Disease Models, Animal; Glucose Transporter Type 4; Glucosides; Insulin Resistance; Isolated Heart Preparation; Male; Mice, Inbred C57BL; Myocardial Reperfusion Injury; Myocytes, Cardiac; Obesity; Phlorhizin; Signal Transduction; Sodium-Glucose Transporter 1; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2019 |
Factors with remission of fatty liver in patients with type 2 diabetes treated with ipragliflozin.
Topics: Aged; Body Mass Index; Diabetes Mellitus, Type 2; Fatty Liver; Female; gamma-Glutamyltransferase; Glucosides; Humans; Male; Middle Aged; Remission Induction; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome; Triglycerides; Waist Circumference | 2019 |
Open-Label Study to Assess the Efficacy of Ipragliflozin for Reducing Insulin Dose in Patients with Type 2 Diabetes Mellitus Receiving Insulin Therapy.
Topics: Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Thiophenes | 2019 |
Ipragliflozin as an add-on therapy in type 2 diabetes mellitus patients: An evidence-based pharmacoeconomics evaluation.
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Economics, Pharmaceutical; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2019 |
Acute and Direct Effects of Sodium-Glucose Cotransporter 2 Inhibition on Glomerular Filtration Rate in Spontaneously Diabetic Torii Fatty Rats.
Topics: Animals; Blood Glucose; Blood Pressure; Chlorides; Creatinine; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Glomerular Filtration Rate; Glucosides; Heart Rate; Male; Rats, Sprague-Dawley; Sodium; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2019 |
SGLT2 inhibitor ipragliflozin attenuates breast cancer cell proliferation.
Topics: Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Gene Knockdown Techniques; Glucosides; Humans; MCF-7 Cells; Membrane Potential, Mitochondrial; Patch-Clamp Techniques; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2020 |
SGLT2 inhibitor ipragliflozin alone and combined with pioglitazone prevents progression of nonalcoholic steatohepatitis in a type 2 diabetes rodent model.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, High-Fat; Disease Progression; Drug Therapy, Combination; Glucosides; Hypoglycemic Agents; Male; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Pioglitazone; Rodentia; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2019 |
Ipragliflozin Ameliorates Endoplasmic Reticulum Stress and Apoptosis through Preventing Ectopic Lipid Deposition in Renal Tubules.
Topics: Animals; Apoptosis; Disease Models, Animal; Down-Regulation; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Glucosides; Heat-Shock Proteins; Male; Mice; Non-alcoholic Fatty Liver Disease; Renal Insufficiency, Chronic; Thiophenes; Transcription Factor CHOP; Triglycerides | 2019 |
Severe intoxication caused by sodium-glucose cotransporter 2 inhibitor overdose: a case report.
Topics: Adult; Drug Overdose; Female; Glucosides; Humans; Hypotension; Kidney; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2020 |
Investigation of efficacy and safety of low-dose sodium glucose transporter 2 inhibitors and differences between two agents, canagliflozin and ipragliflozin, in patients with type 2 diabetes mellitus.
Topics: Aged; Blood Glucose; Blood Pressure; Canagliflozin; Diabetes Mellitus, Type 2; Drug Administration Schedule; Female; Glucosides; Glycated Hemoglobin; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2019 |
Osmotic diuresis by SGLT2 inhibition stimulates vasopressin-induced water reabsorption to maintain body fluid volume.
Topics: Animals; Body Fluid Compartments; Body Fluids; Diuresis; Diuretics, Osmotic; Glucosides; Osmosis; Rats; Renal Reabsorption; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Vasopressins; Water | 2020 |
Long-term efficacy of the sodium-glucose cotransporter 2 inhibitor, ipragliflozin, in a case of type A insulin resistance syndrome.
Topics: Adult; Biomarkers; Blood Glucose; Diabetes Mellitus; Female; Glucosides; Glycated Hemoglobin; Humans; Insulin Resistance; Prognosis; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2020 |
Effects of ipragliflozin on the development and progression of kidney disease in patients with type 2 diabetes: An analysis from a multicenter prospective intervention study.
Topics: Aged; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Follow-Up Studies; Glomerular Filtration Rate; Glucosides; Glycated Hemoglobin; Humans; Male; Middle Aged; Prognosis; Prospective Studies; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2020 |
Mechanisms and prediction of short-term natriuretic effect of sodium-glucose cotransporter 2 inhibitor in heart failure patients coexisting type 2 diabetes mellitus.
Topics: Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Female; Glucosides; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Natriuresis; Natriuretic Agents; Prospective Studies; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Time Factors; Treatment Outcome | 2020 |
Real-World Evidence for Long-Term Safety and Effectiveness of Ipragliflozin in Japanese Patients with Type 2 Diabetes Mellitus: final Results of a 3-Year Post-Marketing Surveillance Study (STELLA-LONG TERM).
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Japan; Product Surveillance, Postmarketing; Thiophenes | 2021 |
Glucose-lowering effects of 7-day treatment with SGLT2 inhibitor confirmed by intermittently scanned continuous glucose monitoring in outpatients with type 1 diabetes. A pilot study.
Topics: Adult; Ambulatory Care; Benzhydryl Compounds; Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Female; Glucosides; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Monitoring, Ambulatory; Pilot Projects; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2021 |
[Short-term Glucose Lowering Effects of Sodium-glucose Cotransporter 2 Inhibitors Confirmed by Flash Glucose Monitoring in Two Outpatients with Type 1 Diabetes].
Topics: Adult; Benzhydryl Compounds; Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 1; Female; Glucosides; Glycemic Control; Humans; Hyperglycemia; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Time Factors; Treatment Outcome | 2020 |
Ipragliflozin, an SGLT2 Inhibitor, Ameliorates High-Fat Diet-Induced Metabolic Changes by Upregulating Energy Expenditure through Activation of the AMPK/ SIRT1 Pathway.
Topics: AMP-Activated Protein Kinases; Animals; Diet, High-Fat; Energy Metabolism; Glucosides; Male; Mice; Sirtuin 1; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2021 |
Effects of SGLT2 inhibitor ipragliflozin alone and combined with pioglitazone on fluid retention in type 2 diabetic mice with NASH.
Topics: Animals; Aquaporin 2; Body Fluids; Diabetes Mellitus, Type 2; Diuresis; Drinking; Glucosides; Hypoglycemic Agents; Male; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Organ Size; Osmolar Concentration; Pioglitazone; Sodium; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2021 |
Effect of ipragliflozin on liver function in Japanese type 2 diabetes mellitus patients: subgroup analysis of a 3-year post-marketing surveillance study (STELLA-LONG TERM).
Topics: Aged; Alanine Transaminase; Aspartate Aminotransferases; Blood Glucose; Diabetes Mellitus, Type 2; Female; gamma-Glutamyltransferase; Glucosides; Glycated Hemoglobin; Humans; Japan; Liver; Liver Function Tests; Male; Middle Aged; Product Surveillance, Postmarketing; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2021 |
Regional Distribution of Cardiologists and Prescription Patterns of Sodium-Glucose Transporter-2 Inhibitors in Japan.
Topics: Aged; Aged, 80 and over; Benzhydryl Compounds; Canagliflozin; Cardiologists; Cardiovascular System; Data Analysis; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Japan; Kidney; Male; Prescriptions; Regression Analysis; Sodium-Glucose Transporter 2 Inhibitors; Sorbitol; Thiophenes | 2021 |
Ipragliflozin Ameliorates Diabetic Nephropathy Associated with Perirenal Adipose Expansion in Mice.
Topics: Adipose Tissue; Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Glucosides; Kidney Glomerulus; Male; Mice; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2021 |
Efficacy and safety of adding ipragliflozin to insulin in Japanese patients with type 1 diabetes mellitus: a retrospective study.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 1; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Japan; Middle Aged; Retrospective Studies; Thiophenes; Treatment Outcome | 2021 |
SGLT2 inhibitor ipragliflozin exerts antihyperglycemic effects via the blood glucose-dependent increase in urinary glucose excretion in type 2 diabetic mice.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Disease Models, Animal; Glucose Tolerance Test; Glucosides; Humans; Male; Mice; Renal Elimination; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2021 |
Peripheral combination treatment of leptin and an SGLT2 inhibitor improved glucose metabolism in insulin-dependent diabetes mellitus mice.
Topics: Administration, Oral; Animals; Diabetes Mellitus, Type 1; Disease Models, Animal; Drug Therapy, Combination; Glucose; Glucosides; Infusions, Intravenous; Leptin; Male; Mice, Inbred C57BL; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2021 |
Effects of GLP-1RA and SGLT2i, Alone or in Combination, on Mouse Models of Type 2 Diabetes Representing Different Disease Stages.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Disease Models, Animal; Drug Therapy, Combination; Glucagon-Like Peptide-1 Receptor; Glucosides; Hypoglycemic Agents; Insulin-Secreting Cells; Liraglutide; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2021 |
Novel and conventional inhibitors of canonical autophagy differently affect LC3-associated phagocytosis.
Topics: Autophagosomes; Autophagy; Cell Differentiation; Chloroquine; Class III Phosphatidylinositol 3-Kinases; Dendritic Cells; Endosomes; Gene Expression Regulation; Humans; Lysosomes; Macrolides; Microtubule-Associated Proteins; Monocytes; Phagocytosis; Phagosomes; Primary Cell Culture; Proteasome Endopeptidase Complex; Pyridines; Pyrimidinones; Thiophenes; Zymosan | 2022 |
Ipragliflozin attenuates non-alcoholic steatohepatitis development in an animal model.
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Blood Glucose; Diabetes Mellitus, Experimental; Disease Models, Animal; Fasting; Gene Expression Profiling; Gene Expression Regulation; Glucosides; Hepatocytes; Hypoglycemic Agents; Interleukin-1beta; Liver; Liver Cirrhosis; Male; Mice; Mice, Inbred C57BL; MicroRNAs; Non-alcoholic Fatty Liver Disease; Signal Transduction; Streptozocin; Superoxide Dismutase; Thiophenes; Tumor Necrosis Factor-alpha | 2022 |
Reply to the Letter to the editor "Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD".
Topics: Diabetes Mellitus; Glucosides; Humans; Non-alcoholic Fatty Liver Disease; Thiophenes | 2022 |
Reply to: "Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD".
Topics: Diabetes Mellitus; Glucosides; Humans; Non-alcoholic Fatty Liver Disease; Thiophenes | 2022 |